WO2002020484A1 - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
WO2002020484A1
WO2002020484A1 PCT/SE2001/001869 SE0101869W WO0220484A1 WO 2002020484 A1 WO2002020484 A1 WO 2002020484A1 SE 0101869 W SE0101869 W SE 0101869W WO 0220484 A1 WO0220484 A1 WO 0220484A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
halogen
compound
substituted
Prior art date
Application number
PCT/SE2001/001869
Other languages
French (fr)
Inventor
Hitesh Sanganee
Brian Springthorpe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to EP01963655A priority Critical patent/EP1322611A1/en
Priority to JP2002525106A priority patent/JP2004508355A/en
Priority to AU2001284584A priority patent/AU2001284584A1/en
Priority to US10/344,758 priority patent/US7304077B2/en
Publication of WO2002020484A1 publication Critical patent/WO2002020484A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings

Definitions

  • the present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.
  • Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a role in the maturation of cells of the immune system. Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif.
  • the chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or ⁇ ) and Cys-Cys (C- C, or ⁇ ) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
  • the C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP -2).
  • IL-8 interleukin-8
  • NAP -2 neutrophil-activating peptide 2
  • the C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP- 1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l ⁇ and l ⁇ (MlP-l ⁇ and MlP-l ⁇ ).
  • chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4.
  • G protein-coupled receptors among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4.
  • Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basopbils store large amounts of Hstarnine. It is recognised that the degranulation of mast cells and basopbils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G- protein coupled receptors, which are of three main types, HI, H2 and H3.
  • Histamine HI antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, especially rhinitis and urticaria. HI antagonists are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and oedema. The antagonists also produce blockade of the actions of histamine on the HI receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.
  • the present invention provides a compound of formula (I):
  • R 5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the
  • Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers).
  • the present invention covers all such isomers and mixtures thereof in all proportions.
  • Suitable salts include acid addition salts .such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate orjc-toluenesulphonate.
  • the compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.
  • Halogen includes fluorine, chlorine, bromine and iodine.
  • Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl, iso-propyl, iso-butyl or tert-butyl.
  • Alkenyl group are; for example, vinyl or allyl.
  • Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl; and cycloalkylalkyl is, for example cyclopropyhnethyl.
  • Alkoxy includes methoxy, ethoxy, n- propoxy, iso-propoxy and tert-butoxy;
  • alkoxycarbonyl includes methoxy- and ethoxy-, carbonyl;
  • haloalkyl includes trifluoromethyl; haloalkoxy includes trifluoromethoxy;
  • cycloalkylamino includes cyclopropyl-, cyclobutyl-, cyclopentyl- or cyclohexylamino;
  • alkylthio includes methyl- or ethylthio;
  • alkylfhioalkyl includes methylthiomethyl;
  • alkylcarbonylamino includes methyl- or ethylcarbonylamino;
  • the 3- to 10-membered saturated or unsaturated ring system in the group R 5 may be monocyclic or polycyclic comprising 2 or more fused rings, examples of which include cyclobutyl, cyclopentyl, cyclohexyl, norbornylenyl, adamantyl, phenyl, naphthyl, furyl, thienyl, pynolyl, 2,5-dihydro-lH-pynolyl (also know as ⁇ 3 -pynoline), thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl (for example in 6-oxo-l,6-dihydro-pyridinyl), pyrimidinyl (for example a pyrimidinedione), pyrazinyl, pyridazinyl
  • the 3- to 10-membered saturated or unsaturated ring system in the group R 5 may be monocyclic or polycyclic comprising 2 or more fused rings, examples of which include cyclobutyl, cyclopentyl, cyclohexyl, norbornylenyl, adamantyl, piperidyl, phenyl, naphthyl, naphthyridinyl, 1,3-benzodioxolyl, pyrazolyl, furanyl, pyridyl, thienyl, indolyl, benzthiazolyl, benzthienyl, 1,2,3-benzthiadiazolyl, benzoxazolyl, benzothiazolyl, chromonyl, imidazolyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyrimidinyl, pyrazolopyrimidinyl, tfaenopyrimidinyl, tMa
  • m and q are both 0.
  • R 1 is phenyl optionally substituted by halogen (such as chloro or fiuoro), C 1- alkyl (such as methyl) or C 1-4 alkoxy (such as methoxy).
  • halogen such as chloro or fiuoro
  • C 1- alkyl such as methyl
  • C 1-4 alkoxy such as methoxy
  • R 2 is hydrogen.
  • R 3 is hydrogen.
  • R 4 is hydrogen or C 1- alkyl; and R 5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted by at least one of C ⁇ -6 alkyl (substituted with S(O) 2 (C 1-6 alkyl), NHS(O) 2 (C 1-6 alkyl) or S(O) 2 NR 13 R 14 ), S(O) 2 (C 1-6 alkyl), S(O) 2 NH(C 1-6 alkyl), NHC(O)(C 1-6 alkyl) or NHS(O) (C 1-6 alkyl); and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C 1- alkyl, C
  • R 10 is hydroxy or NR ⁇ R 12 group; and, R 6 , R 7 R 8 , R 9 , R u , R 12 , R 13 and R 14 are independently hydrogen or C 1-6 alkyl.
  • R 4 is hydrogen or C 1- alkyl
  • R 5 is phenyl substituted by at least one of C 1-6 alkyl (substituted with S(O) 2 (C 1-6 alkyl), NHS(O) 2 (C ⁇ -6 alkyl) or S(O) 2 NR 13 R 14 ), S(O) 2 (C 1-6 alkyl), S(O) 2 NH(C 1-6 alkyl), NHC(O)(C 1-6 alkyl) or NHS(O) 2 (C 1- alkyl); and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C 1-6 alkyl, C 3 .
  • R 6 cycloalkyl, C 1-6 alkoxy, C ⁇ -6 alkoxycarbonyl, C ⁇ - haloalkyl, C 1-6 haloalkoxy, NR 6 R 7 , C -6 cycloalkylamino, C 1-6 alkylthio, C 1-6 alkylthio(C 1-6 alkyl), C 1-6 alkylcarbonylamino, C(O)NR 8 R 9 , sulphonamido (S(O) 2 NH 2 ), (di)C ⁇ - alkylsulphonamido and C(O)R 10 -substituted C 1-6 alkyl or Cj- alkoxy groups;
  • R 10 is hydroxy or NR n R 12 group; and, R 6 , R 7 R 8 , R 9 , R 11 , R 12 , R 13 and R 14 are independently hydrogen or C 1-6 alkyl.
  • R 4 is hydrogen.
  • R 5 is phenyl mono-substituted by C ⁇ -6 alkyl (substituted with
  • R 13 and R 14 are independently hydrogen or C 1-6 alkyl.
  • the invention provides any compound described in a Table or an Example herein, or a pharmaceutically acceptable salt thereof.
  • the present invention provides the a compound listed in Table II or a pharmaceutically acceptable salt thereof, or a solvate of a salt thereof.
  • compounds of Table II can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers) the present invention covers all such isomers and mixtures thereof in all proportions.
  • Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or y -toluenesulphonate.
  • the compounds of the invention can be prepared by reacting a compound of formula (III):
  • a compound of formula (III) can be prepared by reacting a compound of formula (V):
  • compounds of the invention can be prepared by adapting the methods provided in the Examples below.
  • Compounds of formula (III), (IN), (N) and (NI) can be prepared by using or adapting methods described in the art or by adapting the methods provided in the Examples below.
  • the present invention provides processes for the preparation of the compounds of the invention.
  • the compounds of the invention have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferatfve or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).
  • chemokine receptor especially CCR3
  • the compounds of the invention are also HI antagonists and may be used in the treatment of allergic disorders. Examples of these conditions are:
  • obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma ⁇ such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness) ⁇ ; bronchitis ⁇ such as eosinophilic bronchitis ⁇ ; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer
  • COPD chronic
  • arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarifiropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
  • Alzheimer's disease multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.
  • AIDS Acquired Immunodeficiency Syndrome
  • Lupus disorders such as lupus erythematosus or systemic lupus
  • erythematosus Hashimoto's thyroiditis
  • myasthenia gravis myasthenia gravis
  • type I diabetes nephrotic syndrome
  • eosinophilia fascitis hyper I
  • a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).
  • a method for modulating chemokine receptor activity in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof.
  • a method for antagonising HI in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof.
  • the invention also provides a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.
  • the present invention provides the use of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity) or antagonising HI in a warm blooded animal, such as man, or both).
  • the invention further provides the use of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:
  • COPD chronic obstructive pulmonary disease
  • asthma such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma
  • bronchitis such as eosinophilic bronchitis ⁇
  • acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa
  • membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis
  • seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis
  • sarcoidosis farmer's lung and related diseases
  • nasal polyposis fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough
  • (2) (bone and joints) arthrides including
  • Alzheimer's disease multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle; in a warm blooded animal, such as man.
  • AIDS Acquired Immunodeficiency Syndrome
  • Lupus disorders such as lupus erythematosus or systemic lupus
  • erythematosus Hashimoto's thyroiditis
  • myasthenia gravis myasthenia gravis
  • type I diabetes nephrotic syndrome
  • a compound of the invention, or a pharmaceutically acceptable salt thereof is useful in the treatment of asthma ⁇ such as bronchial, allergic, mtrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness) ⁇ ; or rhinitis ⁇ including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis ⁇ .
  • asthma such as bronchial, allergic, mtrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma
  • a compound of the invention, or a pharmaceutically acceptable salt thereof is useful in the treatment of asthma.
  • the present invention also provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis.
  • the present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) or an HI mediated disease state (such as an allergic disorder) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or solvate thereof.
  • a chemokine mediated disease state especially a CCR3 mediated disease state, especially asthma
  • an HI mediated disease state such as an allergic disorder
  • a compound of the invention or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising HI
  • said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition which comprises a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier.
  • a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
  • compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration.
  • topical such as to the lung and/or airways or to the skin
  • the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.
  • a suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between O.lmg and lg of active ingredient.
  • composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.
  • Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of O.Olmgkg "1 to lOOmgkg "1 of the compound, preferably in the range of O.lmgkg "1 to 20mgkg _1 of this invention, the composition being administered 1 to 4 times per day.
  • the intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection.
  • the intravenous dose may be given by continuous infusion over a period of time.
  • each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
  • Buffers such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl ⁇ - cyclodextrin may be used to aid formulation.
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
  • mass spectra generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H) + ;
  • Example 1 This Example illustrates the preparation of 4-(3,4-dichlorophenoxy)piperidine.
  • Step a tert-Butyl 4-(3,4-dichlorophenoxy)-l-piperidinecarboxylate.
  • Example 2 This Example illustrates the preparation of N- ⁇ 3-[4-(3,4-dichlorophenoxy)-l- piperidinyl]propyl ⁇ -3-(methylsulfonyl)benzamide hydrochloride (a salt of Compound 20 of Table I).
  • Step a tert-butyl 3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propylcarbamate
  • Step b 3 - [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropylamine
  • Step (b) The product of Step (b) (0.15g) was dissolved in DMF (4ml). 3-Methylsulphonyl- benzoic acid (0.1 lOg), triethylamine (0.250ml) and PyBrop® (0.350g) were added. After 8 hours at room temperature the solvents were evaporated and the residue redissolved in ethyl acetate. The organics were washed with H 2 O, dried with MgSO 4 and concentrated.
  • Example 3 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidmyl]etl ⁇ yl ⁇ -3-(me1hylsulfonyl)benzamide hydrochloride (a salt of Compound 19 of Table I).
  • Step a fert-Butyl 2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethylcarbamate
  • Step b 2-[4-(3,4-dicMorophenoxy)-l- ⁇ iperidmyl]ethylamine
  • Step c N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l-piperidmyl]e yl ⁇ -3-(methylsulfonyl)benzamide hydrochloride
  • Step b The product of Step b (0.200g) was dissolved in DMF (5ml). 3-Methylsul ⁇ honyl- benzoic acid (0.132g), triethylamine (0.250ml) and PyBrop® (0.420g) were added. After 24 hours at room temperature the solvents were evaporated and the residue redissolved in ethyl acetate. The organics were washed with H 2 O, dried with MgSO 4 and concentrated.
  • Example 4 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl ⁇ -3-[(methylsulfonyl)methyl]benzamide (Compound 5 of Table I).
  • Example 5 This Example illustrates the preparation of N- ⁇ 2-[4-(3 ,4-dichlorophenoxy)- 1 - ⁇ iperidinyl]emyl ⁇ -4-[(methylsulfonyl)methyl]benzarnide (Compound 7 of Table I).
  • Example 6 This Example illustrates the preparation of N-(cyclopropylmethyl)-N- ⁇ 2-[4-(3,4- difluorophenoxy)-l-piperidinyl]ethyl ⁇ -4-fluoro-3-methoxybenzamide (Compound 15 of Table I).
  • Step a tert-Butyl 4-(3,4-difluorophenoxy)-l-piperidinecarboxylate
  • Step b The product of Step b (5g) was dissolved in DMF (27ml) and triethylamine (7.7ml) was added. tert-Butyl 2-bromoethylcarbamate (5.8g) was added and the solution stirred at room temperature for 24 hrs. The solvent was evaporated and the residue dissolved in ethyl acetate and washed with water. The organic phase separated, dried and evaporated. Purification by flash chromatography (dichloromethane : methanol 97:3) gave the sub-title product as an oil (lOg) containing a small amount of DMF. MS: APCI(+ve): 357 (M+H)
  • Step c The product of Step c (lOg) was dissolved in dioxane (114ml) and HC1 (6N) (114ml) was added and the reaction stirred for 2 hours. Organic solvent was evaporated and aqueous NaOH (2M) added. The product was extracted with ethyl acetate, the combined organic extracts dried with Na 2 SO 4 and concentrated to give the sub-title product as an oil (4.65g).
  • Step e N-(Cyclopropylmethyl)-N- ⁇ 2-[4-(3,4-difluorophenoxy)-l-piperidmyl]ethyl ⁇ amine
  • Step d The product of Step d (0.4g) dissolved in MeOH (6ml) was added to cyclopropanecarbaldehyde (0.116ml) and the resulting mixture was stined for 4 hours. The solvent was evaporated, the residue re-dissolved in methanol (6ml) and ⁇ aBH 4 (0.095g) added and the mixture left for 30 minutes. Aqueous sodium hydroxide (IN) was added and the aqueous extracted with diethyl ether. The organic extracts were dried with Na 2 SO 4 , filtered and concentrated to give the sub-title product as an oil (0.493g).
  • Step f N-(Cyclo ⁇ ro ⁇ ylmethyl)-N- ⁇ 2-[4-(3,4-difiuorophenoxy)- 1 -piperidmyljethyl ⁇ -4- fluoro-3 -methoxybenzamide
  • Example 7 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-difluorophenoxy)-l- piperidinyl]ethyl ⁇ -3-(methylsulfonyl)benzamide hydrochloride (a salt of Compound 16 of Table I).
  • the product of Example 6, Step d (0.200g) was dissolved in THF (4ml), 3- methylsulphonylbenzoic acid (0.156g , ⁇ , ⁇ -di-isopropylethylamine (0.407ml) and PyBrop® (0.401g) were added. After 18 hours at room temperature ethyl acetate and aqueous NaHCO 3 solution were added. The product was extracted with ethyl acetate, the combined organic extracts dried with MgSO and concentrated. Purification by reverse phase HPLC (with a gradient eluent system 45% MeCN/NH OAc aq (0.1%) to 95%
  • Example 8 This Example illustrates the preparation of N- ⁇ 3-[4-(3,4-dichlorophenoxy)-l- piperidinyl]propyl ⁇ -2-(2,5-dmydro-l/ -pynol-l-yl)-l,3-benzotm-azole-6-carboxamide (Compound 17 of Table I). Prepared in a similar manner to the method of Example 6, Step fusing the product, of Example 2, Step b and2-(2,5-d ydro-l-H r -pynol-l-yl)-l,3-benzothiazole-6-carboxyhc acid to give the title compound as a solid (0.026g).
  • Step a N- ⁇ 2-[4-(3,4-Difluorophenoxy)- 1 -piperidinyljethyl ⁇ -2,2,2-trifluoroacetamide
  • Step b N- ⁇ 2-[4-(3,4-Difluorophenoxy)- 1 -piperidinyl] ethyl ⁇ -2,2,2-trifluoro-N- methylacetamide
  • Step d N- ⁇ 2-[4-(3,4-difluorophenoxy)-l-piperidinyl]ethyl ⁇ -3-methoxy-N- methylbenzamide hydrochloride
  • Example 10 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl ⁇ -3-hydroxybenzamide (Compound 8 of Table II).
  • Step a N- ⁇ 2-[4-(3,4-dicUorophenoxy)-l-piperidmyl]ethyl ⁇ -3-methoxybenzamide
  • Step b N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl ⁇ -3-hydroxybenzamide
  • Example 11 The present Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)- l-piperidinyl]ethyl ⁇ -3-[2-(dimethylanrmo)-2-oxoethoxy]bejizamide acetate (a salt of Compound 86 of Table II).
  • Example 12 This Example illustrates the preparation of methyl ⁇ 3-[( ⁇ 2-[4-(3,4- dichlorophenoxy)- 1 -piperidinyl] ethyl ⁇ amino)carbonyl]phenoxy ⁇ acetate hydrochloride (a salt of Compound 87 of Table II).
  • Step b a solution of the product from Example 10, Step b (0.250g) and methyl chloroacetate (0.066g) in dimethylformamide (10ml) under nitrogen was added caesium carbonate (0.4g). The reaction was left to stir for 24hours. Water was added and organics extracted into ethyl acetate and dried with MgSO 4 .
  • Example 13 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl ⁇ -3-(2-hydroxyethoxy)benzamide hydrochloride (a salt of Compound 21 of Table I).
  • the isolated product was then converted to title product by dissolving in diethylether, adding ethereal hydrochloric acid and Iriturating from diethylether to give the titled product (0.069g).
  • Example 14 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]emyl ⁇ -3-[(2-hydroxyemyl)sulfonyl]benzamide acetate (a salt of Compound 22 of Table I).
  • Step a 3- ⁇ [2-(tetrahydro-2J ' -pyran-2-yloxy)ethyl]sulfonyl ⁇ benzoic acid
  • Step b N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl ⁇ -3-[(2-hydroxyethyl)- sulfonyljbenzamide acetate
  • Step a To a solution of the product of Step a (0.20g), the product of Example 3, Step b (0.25g) and diisopropylethyl amine (0.33ml) in dichloromethane (5ml) was added PyBrOP® (0.37g) and the mixture stirred for 24 hours. Purification by Biotage® 40M eluting 20% MeC ⁇ /2% 880 ammonia/ 78% dichloromethane gave a colourless oil (0.49g) which was dissolved in trifluoroacetic acid (9ml) and water (1ml) and stined for 15 minutes.
  • Example 16 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidmyl]ethyl ⁇ -3-(2-methoxyethoxy)benzamide hydrochloride (A salt of Compound 12 of Table I).
  • Example 17 This Example illustrates the preparation of tert-butyl 2- ⁇ 3-[( ⁇ 2-[4-(3,4- dichlorophenoxy)- 1 -piperidinyl]ethyl ⁇ amino)carbonyl]phenoxy ⁇ ethylcarbamate acetate (a salt of Compound 23 of Table I).
  • Step a Methyl 3- ⁇ 2-[(tert-butoxycarbonyl)amino]ethoxy ⁇ benzoate
  • Step b 3- ⁇ 2-[(tert-butoxycarbonyl)amino]ethoxy ⁇ benzoic acid
  • Step c tert-butyl 2- ⁇ 3-[( ⁇ 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl ⁇ amino)- carbonyljphenoxy ⁇ ethylcarbamate acetate
  • Example 18 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl ⁇ -3-[(methylsulfonyl)amino]benzamide (Compound 24 of Table I).
  • Step a 3-amino-N- ⁇ 2-[4-(3,4-dichlorophenoxy) ⁇ 1 -piperidinyl]ethyl ⁇ benzamide
  • Step b 3-amino-N- ⁇ 2-[4-(3,4-dichlorophenoxy) ⁇ 1 -piperidinyl]ethyl ⁇ benzamide
  • Step b N- ⁇ 2-[4-(3,4-dicMorophenoxy)-l-piperidinyl]ethyl ⁇ -3-[(methylsulfonyl)amino]- benzamide
  • Example 19 This Example illustrates the preparation of 3 -(2-aminoethoxy)-N- ⁇ 2-[4-(3 ,4- dichlorophenoxy)-l-piperidinyl] ethyl ⁇ benzamide dihydrochloride (a salt of Compound 25 of Table I).
  • step b (0.848g) was then added and the reaction left to stir for 24 hrs.
  • Aqueous NaHCO 3 solution was added and the product extracted with CH 2 C1 2 .
  • the organic phase was washed with H 2 O dried with Na 2 SO and purification by flash chromatography (ethyl acetate: isohexane 30:70) gave the sub-title compound (0.650g).
  • Step b (lS)-2-[4-(3,4-difluorophenoxy)-l-piperidinyl]-2-oxo-l-phenylethylarnine
  • step a (0.650g) was dissolved in dichloromethane
  • Step c ( 1 S)-2-[4-(3 ,4-difluorophenoxy)- 1 -piperidinyl]- 1 -phenylethylamine
  • step b) The product from Example 20, step b) (0.544g) was dissolved in THF (5ml) and borane [10.05ml (IM in THF)] was added. The reaction was heated at reflux for 2 hours. The reaction was quenched slowly with MeOH and the solvents evaporated. Aqueous HCl (5ml Concentrated HCl: 5ml H 2 O) was added and the reaction heated at 70°C for lhour. NaOH (2M) was added until pH 9 was reached. The product was extracted with CH 2 C1 2 and the combined organics washed with saturated aqueous NaHCO , dried with Na 2 SO and solvents evaporated.
  • Example 22 This Example illustrates the preparation of 3-(aminosulfonyl)-N- ⁇ 2-[4-(3,4- dichlorophenoxy)-l-piperidinyl]ethyl ⁇ benzamide.
  • Example 23 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl] ethyl ⁇ - 1 -ethyl-7-methyl-4-oxo- 1 ,4-dihydro [ 1 , 8]naphthyridine-3 -carboxamide. Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 503 (M+H)
  • Example 24 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl ⁇ -2-(4-hydroxyphenyl)acetamide.
  • Example 27 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidmyl]ethyl ⁇ -5-(methylsulfonyl)-2-tMophenecarboxamide.
  • Example 29 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl ⁇ -4-(methylsulfonyl)benzamide.
  • Step a N- ⁇ 2-[4-(3,4-dichlorophenoxy)piperidin-l-yl]ethyl ⁇ -2-hydrazino-2-oxoacetamide.
  • Step b (0.85g) and triethylamine
  • Step b 5-(2-chloroamiino)-N- ⁇ 2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl ⁇ -l,3,4- oxadiazole-2 -carboxamide.
  • Step a 4-(2-C oro-4-fluorophenoxy)piperidine.
  • DEAD (0.90ml) was added to a solution of triphenylphosphine (1.44g), 2-chloro-4- fluorophenol (0.806g) and 4-hydroxy-piperidine-l-carboxylic acid tert-butyl ester(l.Og) in THF at RT.
  • the reaction was stined for 16hrs, HCl (2ml, 4M in dioxan) added and the mixture stirred at RT for 16 hrs.
  • Step b 2-[4-(2-Chloro-4-fluorophenoxy)piperidin-l-yl]ethylamine.
  • Potassium carbonate (1.02g, 0.0074 mol) was added to a solution of the 2-chloro-4- fluorophenoxypiperidine (1.7g, 0.0074 mol) and tert-butyl 2-bromoethylcarbamate (1.65g, 0.0074 mol) strirring at RT.
  • the resulting mixture was stined at RT for 24 hours, diluted with ethyl acetate (200ml) and washed with saturated brine solution (3 x 100ml).
  • the organic layer was dried with MgSO and evaporated under reduced pressure.
  • Step c N- ⁇ 2-[4-(2-Chloro-4-fluorophenoxy)-l-piperidinyl]ethyl ⁇ -6-(lH-pyrazol-l- yl)nicotinamide.
  • Example 33 This Example illustrates the preparation of N- ⁇ 2-[4-(2-chloro-4-fiuorophenoxy)- 1 - piperidinyl]ethyl ⁇ -3-(methylsulfonyl)benzamide.
  • Step b 2- [4-(2,4-Dichloro-3 -methylphenoxy)piperidin- 1 -yl] ethylamine.
  • the sub-titled compound was prepared in a similar manner to Example 32, Step b.
  • Step c N- ⁇ 2-[4-(2,4-DicUoro-3-methylphenoxy)-l-piperidinyl]ethyl ⁇ -4- (methylsulfonyl)benzamide.
  • Example 35 This Example illustrates the preparation of N- ⁇ 2-[4-(2,4-dichloro-3- methylphenoxy)-l-piperidmyl]ethyl ⁇ -5-(methylsulfonyl)-2-t ophenecarboxamide.
  • the title compound was prepared in a similar manner to Example 7 using the product of Example 34, step b.
  • Example 36 This Example illustrates the preparation of N- ⁇ 2-[4-(2,4-dichloro-3- metnylphenoxy)-l-piperidinyl]ethyl ⁇ -2-(methylsulfonyl)benzamide.
  • the title compound was prepared in a similar manner to Example 7 using the product of Example 34, step b.
  • Example 37 This Example illustrates the preparation of N- ⁇ 2-[4-(4-chloro-3-methylphenoxy)-l- piperidinyl] ethyl ⁇ -4-(methylsulfonyl)benzamide. Step a: 4-(4-Chloro-3-methylphenoxy)piperidine.
  • Step b 2-[4-(4-CMoro-3-me ylphenoxy)piperidm-l-yl]ethylamine.
  • This Example illustrates the preparation of N- ⁇ 2-[4-(4-chloro-3-methylphenoxy)-l- piperidinyl]ethyl ⁇ -6-(lH-pyrazol-l-yl)nicotinamide.
  • Example 39 This Example illustrates the preparation of N- ⁇ 2-[4-(4-chloro-3-methylphenoxy)-l- piperidinyl]eti ⁇ yl ⁇ -2-(methylsulfonyl)benzamide.
  • Example 41 This Example illustrates the preparation of 2-cyano-N- ⁇ 2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl]ethyl ⁇ benzamide.
  • the title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
  • Example 42 This Example illustrates the preparation of 2-chloro-N- ⁇ 2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl]ethyl ⁇ -4-(methylsulfonyl)benzamide.
  • Example 43 This Exampleillustrates the preparation of 3-cyano-N- ⁇ 2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl] ethyl ⁇ benzamide.
  • Example 44 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-difluorophenoxy)-l- piperidinyl] ethyl ⁇ -4- [(methy lsulfony l)methyl]b enzamide.
  • the title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
  • Example 45 This Example illustrates the preparation of N- ⁇ 2-[4-(3,4-difluorophenoxy)-l- piperidinyl] ethyl ⁇ -6-( 1 H-pyrazol- 1 -yl)mcotinamide.
  • Human eosinophil chemotaxis Human eosinophil chemotaxis Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., J. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended at lOxlO 6 ml "1 in RPMI containing 200 IU/ml penicillin, 200 ⁇ g/ml streptomycin sulphate and supplemented with 10% HIFCS, at room temperature.
  • Eosinophils 700 ⁇ l were pre-incubated for 15 mins at 37° C with 7 ⁇ l of either vehicle or compound (lOOx required final concentration in 10% DMSO).
  • the chemotaxis plate (ChemoTx, 3 ⁇ m pore, Neuroprobe) was loaded by adding 28 ⁇ l of a concentration of eotaxin (0.1 to lOOnM) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate.
  • the filter was then placed over the wells and 25 ⁇ l of eosinophil suspension were added to the top of the filter.
  • the plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO 2 atmosphere to allow chemotaxis.
  • the medium containing cells that had not migrated, was carefully aspirated from above the filter and discarded.
  • the filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells.
  • Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 rnins at room temperature) and the filter removed and the supernatant transfened to each well of a 96-well plate (Costar).
  • the pelleted cells were lysed by the addition of 28 ⁇ l of PBS containing 0.5% Triton xl 00 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant.
  • the number of eosinophils n ⁇ grating was quantified according to the method of Strath et al., J. Immunol Methods, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.
  • Certain compounds of the Examples were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis.
  • the buffer was maintained at 37°C and gassed with 5% CO 2 in oxygen.
  • Indomethacin (2.8 ⁇ M) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo- oxygenase products.
  • the tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders.
  • E/[A] histamine concentration effect

Abstract

The invention provides compounds of formula (I): as modulators of chemokine and H1 receptor activity. The compounds are especially useful in the treatment of asthma and rhinitis.

Description

CHEMICAL COMPOUNDS
The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.
Pharmaceutically active piperidine derivatives are disclosed in WO99/38514, WO99/04794, WO00/29377, WO00/35877, WO0058305 and WO01/14333.
Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a role in the maturation of cells of the immune system. Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C- C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP -2).
The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP- 1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins lα and lβ (MlP-lα and MlP-lβ).
Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basopbils store large amounts of Hstarnine. It is recognised that the degranulation of mast cells and basopbils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G- protein coupled receptors, which are of three main types, HI, H2 and H3. Histamine HI antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, especially rhinitis and urticaria. HI antagonists are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and oedema. The antagonists also produce blockade of the actions of histamine on the HI receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing. The present invention provides a compound of formula (I):
Figure imgf000003_0001
wherein
R1 is phenyl optionally substituted by cyario, S(O)2(C1-6 alkyl), S(O)2(C1-6 haloalkyl), halogen, C1-6 alkyl, C1-6 haloalkyl or C1-6 alkoxy; n is 0, 1, 2, 3 or 4; m is 0 or 1; when m is 0 then q is 0, and when m is 1 then q is 1, 2 or 3; provided that n + m + q = 1, 2, 3 or 4; when R2 and R3 are, independently, hydrogen or C1-6 alkyl, and R4 is hydrogen, then R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted at least once with a substituent selected from the group comprising: C^ alkyl (substituted with NH2, CO2(Cι_6 alkyl), S(O)2(CI-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), S(O)2(Cι-6 alkyl), S(O)2(Cι-6 hydroxyalkyl), S(O)2NH(Cι-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), C1-6 alkoxy (substituted with C1-6 alkoxy, hydroxy, CO2(Cι-6 alkyl), NHC(O)O(Cι-6 alkyl) or NH2), C2-6 alkenyl, pynolyl and Δ3- pynolinyl; and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1-6 alkyl, C3-6 cycloalkyl, Cj-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 haloalkyl, C1-6 haloalkoxy, NR6R7, C3-6 cycloalkylamino, C1-6 alkylthio, Cι-6 alkylthio(Cι.6 alkyl), C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, and C(O)R10-substituted C1-6 alkyl or Cι-6 alkoxy groups; when R2 and R3 are, independently, hydrogen or Cι-6 alkyl, and R4 is C1- alkyl or C3-6 cycloalkyl(C1-4 alkyl), then R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, C\. 6 alkyl (optionally substituted with halogen, C1-6 alkylthio, NH2, C(O)R10, CO2(C1-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(Cl-6 alkyl) or S(O)2NR13R14), C3-6 cycloalkyl, C1-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(C1-6 alkyl), NHC(O)O(C1-6 alkyl) orNH ), C2- alkenyl, C1-6 alkoxycarbonyl, NR6R7, C3-6 cycloalkylamino, C1-6 allcylthio, C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or Δ -pynolinyl; and when R2 is phenyl (optionally substituted with halogen, C1- alkyl or C1- alkoxy), R3 is hydrogen or C1-6 alkyl, and R4 is hydrogen, C1- alkyl or C -6 cycloalkyl(CM alkyl), then R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, C1-6 alkyl (optionally substituted with halogen, d-6 alkylthio, NH2, C(O)R10, CO2(Cι-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), C3-6 cycloalkyl, C1-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(C1-6 alkyl), NHC(O)O(d-6 alkyl) or NH2), C2-6 alkenyl, Ci_6 alkoxycarbonyl, NR6R7, C3-6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylcarbonylamino, C(O)NRsR9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1- alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or Δ3 -pynolinyl; R10 is hydroxy or NRUR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or C1-6 alkyl; or a pharmaceutically acceptable salt thereof; or a solvate thereof.
Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions. Suitable salts include acid addition salts .such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate orjc-toluenesulphonate.
The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates. Halogen includes fluorine, chlorine, bromine and iodine.
Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl, iso-propyl, iso-butyl or tert-butyl. Alkenyl group are; for example, vinyl or allyl.
Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl; and cycloalkylalkyl is, for example cyclopropyhnethyl. Alkoxy includes methoxy, ethoxy, n- propoxy, iso-propoxy and tert-butoxy; alkoxycarbonyl includes methoxy- and ethoxy-, carbonyl; haloalkyl includes trifluoromethyl; haloalkoxy includes trifluoromethoxy; cycloalkylamino includes cyclopropyl-, cyclobutyl-, cyclopentyl- or cyclohexylamino; alkylthio includes methyl- or ethylthio; alkylfhioalkyl includes methylthiomethyl; alkylcarbonylamino includes methyl- or ethylcarbonylamino; C(O)NR8R9 includes C(O)NHCH ; dialkylsulphonamido includes dimethylsulphonamido and diethylsulphonamido; alkyl substituted with NH2 includes CH NH ; alkyl substituted with CO2(alkyl) includes CH2CO2CH3; alkyl substituted with S(O)2(alkyl) includes CH2S(O)2CH3 and CH2S(O)2CH2CH3; alkyl substituted with NHS(O)2(alkyl) includes CH2NHS(O)2CH3; alkyl substituted with S(O)2NR13R14 includes CH2S(O)2N(CH3)2; S(O)2(alkyl) includes S(O)2CH3 and S(O)2CH2CH3; S(O)2(hydroxyalkyl) includes S(O)2CH2CH2OH; S(O)2NH(alkyl) includes S(O)2NHCH3; NHC(O)(alkyl) includes NHC(O)CH3; NHS(O)2(alkyl) includes NHS(O)2CH3; alkoxy substituted with alkoxy includes O(CH2)2OCH3; alkoxy substituted with hydroxy includes O(CH2)2OH; alkoxy substituted with CO2(alkyl) OCH2CO2CH3; alkoxy substituted with NHC(O)O(alkyl) includes OCH2NHCO2CH3; and alkoxy substituted withNH2 includes OCH2NH2.
The 3- to 10-membered saturated or unsaturated ring system in the group R5 may be monocyclic or polycyclic comprising 2 or more fused rings, examples of which include cyclobutyl, cyclopentyl, cyclohexyl, norbornylenyl, adamantyl, phenyl, naphthyl, furyl, thienyl, pynolyl, 2,5-dihydro-lH-pynolyl (also know as Δ3-pynoline), thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl (for example in 6-oxo-l,6-dihydro-pyridinyl), pyrimidinyl (for example a pyrimidinedione), pyrazinyl, pyridazinyl, indolyl, 2,3-dihydroindolyl, benzofb] furyl, benz[b]thienyl, 2,3-dihydrobenz[b]thienyl (for example in l-dioxo-2,3- dihydrobenz[b]thienyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl (for example in lH-benzthiazol-2-one-yl), 2,3-dihydrobenzthiazolyl (for example in 2,3-dihydrobenzthiazol-2-one-yl), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[l,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl, benzo[l,2,3]thiadiazolyl, 2,1,3-benzofhiadiazolyl, benzofurazan, quinoxalinyl, dihydro-1-benzopyryliumyl (for example in a coumarinyl or a chromonyl), 3,4-dihydro-lH-2,l-benzothiazinyl (for example in 2-dioxό-3,4-dihydro-lH-2,l-benzothiazinyl), a pyrazolopyridine (for example 1H- pyrazolo[3,4-b]pyridinyl), a purine (for example in 3,7-dihydro-purin-2,6-dione-8-yl), a pyrazolopyrimidinyl, a thienopyrimidinyl, a tMazolopvrimidinyl, quinolinyl, isoquinolinyl (for example in 2H-isoquinolin-l-one-yl), quinoxalinyl (for example 2,4-dioxo-3, 4- dihydro-quinazolinyl), a naphthyridinyl (for example [l,6]naphthyridinyl or [l,8]naphthyridinyl or in lH-[l,8]naphthyridin-4-one-yl), chromonyl, 1,3-benzodioxolyl, a benzothiazinyl (for example in 4H-benzo[l,4]thiazin-3-one-yl), benzo[d]imidazo[2,l- b]thiazol-2-yl or dibenzothiophenyl; or an N-oxide thereof, or an S-oxide or S-dioxide thereof.
Alternatively, the 3- to 10-membered saturated or unsaturated ring system in the group R5 may be monocyclic or polycyclic comprising 2 or more fused rings, examples of which include cyclobutyl, cyclopentyl, cyclohexyl, norbornylenyl, adamantyl, piperidyl, phenyl, naphthyl, naphthyridinyl, 1,3-benzodioxolyl, pyrazolyl, furanyl, pyridyl, thienyl, indolyl, benzthiazolyl, benzthienyl, 1,2,3-benzthiadiazolyl, benzoxazolyl, benzothiazolyl, chromonyl, imidazolyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyrimidinyl, pyrazolopyrimidinyl, tfaenopyrimidinyl, tMazolopyrimidinyl, pyrimidinedione, pyrazinyl, pyridazinyl, purinyl, quinoxalinyl, thiazolyl, isothiazolyl and 2,4-dioxo-3,4-dihydro- quinazolinyl. Δ3 -Pynoline is also known as 2,5-dihydro-lϋf-pynole and has the structure:
Figure imgf000006_0001
In one aspect m and q are both 0.
In another aspect the present invention provides a compound of formula (I) wherein R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(C1-6 haloalkyl), halogen, C1- alkyl, Cι-6 haloalkyl or C1-6 alkoxy; n is 0, 1, 2, 3 or 4; m is 0 or 1; when m is 0 then q is 0, and when m is 1 then q is 1, 2 or 3; provided that n + m + q = 1, 2, 3 or 4; R2 and R3 are, independently, hydrogen or Cι-6 alkyl; R4 is hydrogen; R5 is a 3- to 10- membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted at least once with a substituent selected from the group comprising: C1- alkyl (substituted withNH2, CO2(Cι-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(Cι-6 alkyl) or S(O)2NR13R14), S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), C1-6 alkoxy (substituted with C1-6 alkoxy, hydroxy, CO2(C1-6 alkyl), NHC(O)O(Cι-6 alkyl) orNH2), C2-6 alkenyl, pynolyl and Δ3- pynolinyl; and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1-6 alkyl, C3- cycloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 haloalkyl, C1-6 haloalkoxy, NR°R7, C3-6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylthio(C1-6 alkyl), Cι-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, and C(O)R10-substituted C1-6 alkyl or C1-6 alkoxy groups; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or Cι-6 alkyl.
In a further aspect the present invention provides a compound of formula (I) wherein R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(Cι-6 haloalkyl), halogen, C1-6 alkyl, C1-6 haloalkyl or Cι-6 alkoxy; n is 0, 1, 2, 3 or 4; m is 0 or 1; when m is 0 then q is 0, and when m is 1 then q is 1, 2 or 3; provided that n + m + q = 1, 2, 3 or 4; R2 and R3 are, independently, hydrogen or C1-6 alkyl; R4 is C1-4 alkyl or C3-6 cyeloalkyl(C1- alkyl); R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, Ci- 6 alkyl (optionally substituted with halogen, C1-6 alkylthio, NH2, C(O)R10, CO2(Cι-6 alkyl), S(O)2(Cι-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), C3-6 cycloalkyl, Cι-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(Cι-6 alkyl), NHC(O)O(C1-6 alkyl) or NH2), C2- alkenyl, Cι-6 alkoxycarbonyl, NR6R7, C3-6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(Cι-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(Cι-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or Δ3 -pynolinyl; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or . β alkyl.
In a still further aspect the present invention provides a compound of formula (I) wherein R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(C1-6 haloalkyl), halogen, C1-6 alkyl, C1-6 haloalkyl or C1-6 alkoxy; n is 0, 1, 2, 3 or 4; m is 1; q is 1 ; provided that n + m + q = 2, 3 or 4; R2 is phenyl (optionally substituted with halogen, CM alkyl or Cμ alkoxy); R3 is hydrogen or C1-6 alkyl; R4 is hydrogen, C1-4 alkyl or C3-6 alkyl); R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, Cχ_ 6 alkyl (optionally substituted with halogen, C1-6 alkylthio, NH2, C(O)R10, CO2(C1-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), C3-6 cycloalkyl, C1-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(C1-6 alkyl), NHC(O)O(C1-6 alkyl) or NH ), C2- alkenyl, Cι-6 alkoxycarbonyl, NR6R7, C3-6 cycloaJJcylamino, C1-6 alkylthio, C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(Cι-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(Cι-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or Δ3 -pynolinyl; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or Ci. 6 alkyl.
In another aspect R1 is phenyl optionally substituted by halogen (such as chloro or fiuoro), C1- alkyl (such as methyl) or C1-4 alkoxy (such as methoxy). In a further aspect n is 2.
In yet another aspect R2 is hydrogen. In a still further aspect R3 is hydrogen. In another aspect R4 is hydrogen or C1- alkyl; and R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted by at least one of Cι-6 alkyl (substituted with S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), S(O)2(C1-6 alkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl) or NHS(O) (C1-6 alkyl); and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1- alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 haloalkyl, C1-6 haloalkoxy, NR6R7, C3.6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylthio(C1-6 alkyl), C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido and C(O)R10-substituted C1-6 alkyl or C1-6 alkoxy groups; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9, Ru, R12, R13 and R14 are independently hydrogen or C1-6 alkyl.
In yet another aspect R4 is hydrogen or C1- alkyl; and R5 is phenyl substituted by at least one of C1-6 alkyl (substituted with S(O)2(C1-6 alkyl), NHS(O)2(Cι-6 alkyl) or S(O)2NR13R14), S(O)2(C1-6 alkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl) or NHS(O)2(C1- alkyl); and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1-6 alkyl, C3.6 cycloalkyl, C1-6 alkoxy, Cι-6 alkoxycarbonyl, Cι- haloalkyl, C1-6 haloalkoxy, NR6R7, C -6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylthio(C1-6 alkyl), C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)Cι- alkylsulphonamido and C(O)R10-substituted C1-6 alkyl or Cj- alkoxy groups; R10 is hydroxy or NRnR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or C1-6 alkyl.
In a further aspect of the invention R4 is hydrogen. In a still further aspect R5 is phenyl mono-substituted by Cι-6 alkyl (substituted with
S(O)2(Cι-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), S(O)2(C1-6 alkyl), S(O)2NH(C1-6 alkyl), NHC(O)(Cι-6 alkyl) or NHS(O)2(C1-6 alkyl); and R13 and R14 are independently hydrogen or C1-6 alkyl.
In another aspect the invention provides any compound described in a Table or an Example herein, or a pharmaceutically acceptable salt thereof.
Compounds of the invention are listed in Table I. All the compounds in Table I are compounds of formula (I) wherein m and q are both 0. TABLE I
Figure imgf000010_0001
In a further aspect the present invention provides the compounds listed in Table II which are o f formula (II) :
Figure imgf000011_0001
TABLE π
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000013_0002
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000017_0003
Figure imgf000017_0002
Figure imgf000018_0002
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000021_0001
Figure imgf000021_0003
Figure imgf000021_0002
Figure imgf000022_0001
Figure imgf000022_0003
Figure imgf000022_0002
In a further aspect the present invention provides the a compound listed in Table II or a pharmaceutically acceptable salt thereof, or a solvate of a salt thereof. Where compounds of Table II can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers) the present invention covers all such isomers and mixtures thereof in all proportions. Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or y -toluenesulphonate.
The compounds of the invention can be prepared by reacting a compound of formula (III):
Figure imgf000023_0001
with a compound of formula (IN):
O
II 5
L— U—R5 (IV) wherein L is a leaving group (such as halogen). A compound of formula (III) can be prepared by reacting a compound of formula (V):
(V)
Figure imgf000023_0002
wherein L is a leaving group (such as halogen); with a compound of formula (NI):
Figure imgf000023_0003
Alternatively, compounds of the invention can be prepared by adapting the methods provided in the Examples below. Compounds of formula (III), (IN), (N) and (NI) can be prepared by using or adapting methods described in the art or by adapting the methods provided in the Examples below.
In another aspect the present invention provides processes for the preparation of the compounds of the invention.
The compounds of the invention have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferatfve or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).
The compounds of the invention are also HI antagonists and may be used in the treatment of allergic disorders. Examples of these conditions are:
(1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
(2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarifiropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
(3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, sebonhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epideimolysis bullosa, urticaria, angiode mas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis; (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food- related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
(5) (Allograft rejection) acute and' chronic following, for example, transplantation of kidney, heart, liver, lung, bone manow, skin or cornea; or chronic graft versus host disease; and/or
(6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle. According to a further feature of the invention there is provided a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).
According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (especially CCR3 receptor activity) in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof.
According to another feature of the present invention there is provided a method for antagonising HI in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof.
The invention also provides a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament. In a further aspect the present invention provides the use of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity) or antagonising HI in a warm blooded animal, such as man, or both). The invention further provides the use of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:
(1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma
(for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough; (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis; (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, sebonhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
(4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food- related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
(5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone manow, skin or cornea; or chronic graft versus host disease; and/or
(6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle; in a warm blooded animal, such as man.
In a further aspect a compound of the invention, or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma {such as bronchial, allergic, mtrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.
In a still further aspect a compound of the invention, or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma. The present invention also provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis.
The present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) or an HI mediated disease state (such as an allergic disorder) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or solvate thereof.
In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising HI, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound as hereinbefore defined or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.
A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between O.lmg and lg of active ingredient.
In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.
Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of O.Olmgkg"1 to lOOmgkg"1 of the compound, preferably in the range of O.lmgkg"1 to 20mgkg_1 of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
The following illustrate representative pharmaceutical dosage forms containing the compound as hereinbefore defined or a pharmaceutically-acceptable salt thereof (hereafter Compound X), for therapeutic or prophylactic use in humans: (a)
Figure imgf000028_0001
( )
Figure imgf000029_0001
Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β- cyclodextrin may be used to aid formulation. The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
The invention will now be illustrated by the following non-Hmiting Examples in which, unless stated otherwise:
(i) when given, 1H NMR data is quoted in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to teframethylsilane (TMS) as an internal standard;
(ii) mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)+;
(iii) the title and sub-titled compounds of the examples and methods were named using the ACD/name program from Advanced Chemical Development Inc, Canada; (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Ex-Tena reverse phase silica column; (v) solvents were dried with MgSO or Na2SO4;
(vi) unless otherwise stated reactions were performed at room temperature (RT); and, (vii) the following abbreviations are used: THF tetrahydrofuran;
DMF N,N-dimethylformainide DEAD diethyl-azodicarboxylate
TFA trifluoroacetic acid
PyBrop® Bromo-tris-pynolidino-phosphom'um hexafluorophosphate HPLC High pressure liquid chromatography
Example 1 This Example illustrates the preparation of 4-(3,4-dichlorophenoxy)piperidine.
Step a: tert-Butyl 4-(3,4-dichlorophenoxy)-l-piperidinecarboxylate.
Diethyl azodicarboxylate (41.0ml) was added to a solution of triphenylphosphine (62.9g) in THF (800ml) at 0°C. After 15 minutes 3,4-dichlorophenol (39.1g) was added, after a further 15 minutes tert-butyl 4-hydroxy-l-piperidinecarboxylate (48.3 g) in THF (400ml) was added dropwise over 30 minutes. The solution was stined at room temperature for 16 hours and concentrated to a small volume. Purification by flash chromatography (ethyl acetate: isohexane 95:5) gave the sub-title compound as an oil (6L3g). MS: APCI (+ve): 246 (M-BOC+2H) Step b: 4-(3 ,4-Dichlorophenoxy)piperidine
The product from Step (a) was dissolved in dichloromethane (600ml) and trifluoroacetic acid (300ml) was added. After 24 hours at room temperature the solution was evaporated and the resultant gum triturated under ether to give the sub-titled product as a solid (36.6g). The free base was liberated by addition of aqueous NaOH (2M) and extraction with ethyl acetate followed by evaporation of solvent to give the title compound as a gum (25g). lH NMR: (CDC13): δ 1.77 (1H, br s), 2.05-2.26 (4H, m), 3.20-3.49 (4H, ), 4.61 (1H, s), 6.69-7.52 (3H, m).
Example 2 This Example illustrates the preparation of N-{3-[4-(3,4-dichlorophenoxy)-l- piperidinyl]propyl}-3-(methylsulfonyl)benzamide hydrochloride (a salt of Compound 20 of Table I). Step a: tert-butyl 3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propylcarbamate
The product from Example 1 Step (b) (lOg) was dissolved in DMF (50ml) and triethylamine (14.8ml) was added. tert-Butyl 3-bromopropylcarbamate (lOg) was added and the solution stirred at room temperature for 24 hrs. The solvent was evaporated and the resulting solid was dissolved in ethyl acetate and water was added, the organic phase separated, dried with MgSO4 and evaporated to a solid (17.51g). M: ESI (+ve): 403 (M+H)
Step b: 3 - [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropylamine
The product from Step (a) (2g) was dissolved in dioxane (100ml) and 6Ν HC1 (100ml) added. After 1 Shours at room temperature the solvent was evaporated and the resultant solid basified with NaOH (2N) to pH 11. The aqueous was extracted with ethyl acetate, the organic phase separated, dried with MgSO and evaporated to leave the subtitle compound as an oil (l.lg).
MS: ESI (+ve): 303 (M+H) Step c: N- {3-[4-(3,4-dichlorophenoxy)~ 1 -piperidinyl]propyl} -3- (methylsulfonyl)benzamide hydrochloride
The product of Step (b) (0.15g) was dissolved in DMF (4ml). 3-Methylsulphonyl- benzoic acid (0.1 lOg), triethylamine (0.250ml) and PyBrop® (0.350g) were added. After 8 hours at room temperature the solvents were evaporated and the residue redissolved in ethyl acetate. The organics were washed with H2O, dried with MgSO4 and concentrated. Purification by reverse phase HPLC (with a gradient eluent system (25% MeCΝ/ΝH4OAcaq (0.1%) to 95% MeCN//NH4OAcaq (0.1%)) and formation of the hydrochloride salt by addition of HC1 dissolved in ether and evaporation of solvent gave the title compound (0.145g).
MS : APCI (+ve): 485 (M+H).
1H NMR (400MHz, DMSO): δ 1.93 - 2.08 (4H, m), 2.14 - 2.26 (2H, m), 3.11 - 3.20 (4H, m), 3.22 (3H, s), 3.33 - 3.39 (1H, m), 3.41 (2H, q), 3.50 - 3.57 (1H, m), 4.76 - 4.80 (1H, m), 7.02 (1H, dd), 7.25 - 7.32 (1H, m), 7.47 - 7.53 (1H, m), 7.74 (1H, t), 8.06 (1H, dt), 8.19 (1H, dt), 8.39 (1H, t), 8.74 - 8.80 (1H, m). Melting point: 212°C
Example 3 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidmyl]etlιyl}-3-(me1hylsulfonyl)benzamide hydrochloride (a salt of Compound 19 of Table I).
Step a: fert-Butyl 2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethylcarbamate
The product from Example 1 Step (b) (8.6g) was dissolved in DMF (60ml) and triethylamine (12ml) was added. tert-Butyl 2-bromoethylcarbamate (7.8g) was added and the solution stirred at room temperature for 12 hours. Diethyl ether H2O (1:1 500ml) added and the organic phase separated, dried with MgSO4 and evaporated to a gum. Purification by flash chromatography (dichloromethane: methanol: 880 ΝH3 (aq) 98.5:1:0.5) gave the sub-title product (lOg). MS: APCI (+ve): 389(M+H)
Step b: 2-[4-(3,4-dicMorophenoxy)-l-ρiperidmyl]ethylamine
The product from Step a (lOg) was dissolved in dichloromethane (200ml) and trifluoroacetic acid (100ml) added. After 12hours at room temperature the solvent was evaporated and the resultant solid was washed with diethyl ether and filtered. The solid , was redissolved in H2O, basified with NaOH (2N) to pH 11. The aqueous was extracted with dichloromethane, the organic phase separated, dried and evaporated to leave the subtitle compound (3.5g). MS: APCI (+ve): 289 (M+H)
Step c: N-{2-[4-(3,4-dichlorophenoxy)-l-piperidmyl]e yl}-3-(methylsulfonyl)benzamide hydrochloride
The product of Step b (0.200g) was dissolved in DMF (5ml). 3-Methylsulρhonyl- benzoic acid (0.132g), triethylamine (0.250ml) and PyBrop® (0.420g) were added. After 24 hours at room temperature the solvents were evaporated and the residue redissolved in ethyl acetate. The organics were washed with H2O, dried with MgSO4 and concentrated. Purification by reverse phase HPLC (with a gradient eluent system (25% MeCΝ/ΝH4OAcaq (0.1%) to 95% MeCN//NH^OAcaq (0.1%)) (any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with MgSO4 and evaporation of solvent) and formation of the hydrochloride salt by addition of HC1 dissolved in ether and evaporation of solvent gave the title compound (0.084g). MS: APCI (+ve): 471 (M+H)
JH NMR: (399.979 MHz, D2O) δ 2.09 - 2.19 (2H, m), 2.25 - 2.33 (2H, ), 3.30 (3H, s), 3.38 - 3.46 (2H, ), 3.48 (2H, t), 3.58 - 3.66 (2H, m), 3.80 - 3.91 (3H, m), 6.98 (1H, dd), 7.25 (1H, d), 7.47 (1H, d), 7.82 (1H, t), 8.17 (2H, t), 8.36 (1H, s). Melting point: 219°C
Example 4 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-3-[(methylsulfonyl)methyl]benzamide (Compound 5 of Table I).
The product of Example 3, Step (b) (0.200g) was dissolved in dichloromethane (4ml). 3-[(Methylsulfonyl)methyl]benzoic acid (see WO00/15609; or by hydrolysis of methyl 3-[(methylsulfonyl)methyl]benzoate which is commercially available; 0.132g), triethylamine (0.289ml) and PyBrop® (0.483g) were added. After 24 hours at room temperature ΝaHCO3(aq) was added and product extracted with diethyl ether. The organics were dried with MgSO4 and concentrated. Purification by reverse phase HPLC (with a gradient eluent system (25% MeCN/NH OAcaq (0.1%) to 95% MeCNZ/NKiOAcaq (0.1%)) (any excess NH OAc was removed by dissolving the compound in dichloromethane and washing with aqueous saturated NaHCO3 followed by drying of the organics with MgSO and evaporation of solvent) gave the title compound (O.lOlg). MS: APCI(+ve): 485 (M+H).
1H NMR (299.946 MHz, DMSO) δ 1.58 - 1.67 (2H, m), 1.89 - 1.97 (2H, m), 2.27 - 2.35 (2H, m), 2.49 - 2.53 (2H, m), 2.70 - 2.79 (2H, ), 2.94 (3H, s), 3.38 - 3.43 (2H, m), 4.41 - 4.49 (IH, m), 4.54 (2H, s), 4.81-4.83 (IH, m) 6.96 - 7.00 (IH, m), 7.25 - 7.27 (IH, m), 7.47 - 7.57 (3H, m), 7.82 - 7.87 (2H, m), 8.42 - 8.47 (IH, m). Melting point: 112-114°C
Example 5 This Example illustrates the preparation of N- {2-[4-(3 ,4-dichlorophenoxy)- 1 - ρiperidinyl]emyl}-4-[(methylsulfonyl)methyl]benzarnide (Compound 7 of Table I).
Prepared in a similar manner to the method of Example 4 using 4- [(methylsulfonyl)methyl]benzoic acid (J. Med. Chem. (1997), 40(25), 4030-4052) to give the title compound as a solid (0.160g). MS : APCI(+ve): 485 (M+H)
1H ΝMR (299.946 MHz, DMSO) δ 1.56 - 1.65 (2H, m), 1.89 - 1.98 (2H, m), 2.26 - 2.35 (2H, m), 2.65 - 2.82 (2H, m), 2.71 - 2.78 (2H, m), 2.92 (3H, s), 3.37 - 3.41 (2H, m), 4.40 - 4.49 (IH, m), 4.56 (2H, s), 6.96 - 7.00 (IH, m), 7.24 - 7.27 (IH, m), 7.48 - 7.53 (3H, m), 7.82 - 7.86 (2H, m), 8.42 - 8.47 (IH, m). Melting point: 179-181°C.
Example 6 This Example illustrates the preparation of N-(cyclopropylmethyl)-N-{2-[4-(3,4- difluorophenoxy)-l-piperidinyl]ethyl}-4-fluoro-3-methoxybenzamide (Compound 15 of Table I). Step a: tert-Butyl 4-(3,4-difluorophenoxy)-l-piperidinecarboxylate
The sub-title compound was prepared according to the method of Example 1, Step a using 3,4-difluorophenol to afford an oil (5.4g). MS: ESI (+ve): 213 (M-BOC+H)
Step b: 4-(3,4-Difluorophenoxy)piperidine
The sub-title compound was prepared according to the method of Example 1, Step b to afford a pale yellow oil (3g). MS:. ESI (+ve): 214 (M+H) Step c: tert-butyl 2- [4-(3 ,4-difluorophenoxy)- 1 -piperidinyl] ethylcarbamate
The product of Step b (5g) was dissolved in DMF (27ml) and triethylamine (7.7ml) was added. tert-Butyl 2-bromoethylcarbamate (5.8g) was added and the solution stirred at room temperature for 24 hrs. The solvent was evaporated and the residue dissolved in ethyl acetate and washed with water. The organic phase separated, dried and evaporated. Purification by flash chromatography (dichloromethane : methanol 97:3) gave the sub-title product as an oil (lOg) containing a small amount of DMF. MS: APCI(+ve): 357 (M+H)
Step d: 2-[4-(3,4-Difluorophenoxy)-l-piperidmyl]ethylamine
The product of Step c (lOg) was dissolved in dioxane (114ml) and HC1 (6N) (114ml) was added and the reaction stirred for 2 hours. Organic solvent was evaporated and aqueous NaOH (2M) added. The product was extracted with ethyl acetate, the combined organic extracts dried with Na2SO4 and concentrated to give the sub-title product as an oil (4.65g). lE NMR: (400 MHz, CDC13) δ 1.74-1.83 (2H, m), 1.95-2.00 (2H, m), 2.26-2.31 (2H, m), 2.43 (2H, t), 2.73 (2H, br s), 2.79 (2H, t), 4.17-4.23 (IH, m), 6.58-7.07 (3H, m).
MS: APCI(+ve): 257 (M+H)
Step e: N-(Cyclopropylmethyl)-N-{2-[4-(3,4-difluorophenoxy)-l-piperidmyl]ethyl}amine
The product of Step d (0.4g) dissolved in MeOH (6ml) was added to cyclopropanecarbaldehyde (0.116ml) and the resulting mixture was stined for 4 hours. The solvent was evaporated, the residue re-dissolved in methanol (6ml) and ΝaBH4 (0.095g) added and the mixture left for 30 minutes. Aqueous sodium hydroxide (IN) was added and the aqueous extracted with diethyl ether. The organic extracts were dried with Na2SO4, filtered and concentrated to give the sub-title product as an oil (0.493g).
MS: APCI(+ve): 311 (M+H)
Step f: N-(Cycloρroρylmethyl)-N- {2-[4-(3,4-difiuorophenoxy)- 1 -piperidmyljethyl} -4- fluoro-3 -methoxybenzamide
To a solution of 4-fiuoro-3-methoxybenzoic acid (0.082g) in THF (1ml) was added carbonyldiimidazole (0.078g) and the resulting solution stirred at room temperature for 10 minutes before addition of the product of Step e (0.15g) in THF (1.5ml). The mixture was stined for 2 hours and the solvent removed by evaporation to yield a colourless gum. Purification by reverse phase HPLC (with a gradient eluent system 25% MeCN/NH4OAc(aq) (0.1%) to 95% MeCN/ NH4OAc(aq) (0.1%)) gave the title compound (0.01 lg).
MS: ESI(+ve) 463(M+H) lH NMR (300 MHz, CDC13) δ 0.13 - 0.22 (2H, m), 0.52 - 0.58 (2H, m), 0.93 - 1.04 (IH, m), 1.70 - 1.81 (2H, m), 1.88 - 1.99 (2H, m), 2.25 - 2.40 (2H, m), 2.55 - 2.79 (4H, ), 3.22 - 3.33 (2H, m), 3.59 - 3.71 (2H, m), 3.90 (3H, s), 4.14 - 4.22 (IH, m), 6.55 - 6.61 (IH, m), 6.70 (IH, ddd), 6.92 (IH, ddd), 7.01 - 7.06 (2H, m), 7.08 (IH, d).
Example 7 This Example illustrates the preparation of N-{2-[4-(3,4-difluorophenoxy)-l- piperidinyl]ethyl}-3-(methylsulfonyl)benzamide hydrochloride (a salt of Compound 16 of Table I). The product of Example 6, Step d (0.200g) was dissolved in THF (4ml), 3- methylsulphonylbenzoic acid (0.156g , Ν,Ν-di-isopropylethylamine (0.407ml) and PyBrop® (0.401g) were added. After 18 hours at room temperature ethyl acetate and aqueous NaHCO3 solution were added. The product was extracted with ethyl acetate, the combined organic extracts dried with MgSO and concentrated. Purification by reverse phase HPLC (with a gradient eluent system 45% MeCN/NH OAcaq (0.1%) to 95%
MeCN//NHιOAcaq (0.1%)) and formation of the hydrochloride salt by addition of HC1 dissolved in ether and evaporation of solvent gave the title compound (0.205g). MS: APCI(+ve) 439 (M+H)
1H NMR (300 MHz, DMSO) δ 1.93-2.26 (4H, m), 3.05-3.76 (10H, m), 4.50-4.60 (IH, m), 4.76 (IH, brs), 6.81-8.50 (7H, m), 9.29-9.33 (IH, m), 10.81 (IH, br s).
Example 8 This Example illustrates the preparation of N-{3-[4-(3,4-dichlorophenoxy)-l- piperidinyl]propyl}-2-(2,5-dmydro-l/ -pynol-l-yl)-l,3-benzotm-azole-6-carboxamide (Compound 17 of Table I). Prepared in a similar manner to the method of Example 6, Step fusing the product, of Example 2, Step b and2-(2,5-d ydro-l-Hr-pynol-l-yl)-l,3-benzothiazole-6-carboxyhc acid to give the title compound as a solid (0.026g). MS: ESI(+ve) 531 (M+H) 1H NMR: (399.978 MHz, CDC13) δ 1.66 - 2.25 (6H, m), 2.11 - 2.24 (2H, m), 2.72 - 2.83 (3H, m), 2.85 - 2.95 (2H, m), 3.64 (2H, q), 4.37 -.4.45 (IH, m), 6.41 (2H, t), 6.75 (IH, dd), 7.00 (IH, d), 7.21 (2H, d), 7.47 (2H, t), 7.89 (IH, d), 7.94 - 7.96 (IH, m), 8.39 (IH, s), 8.42 - 8.47 (IH, m). Example 9
This Example illustrates the preparation of N-{2-[4-(3,4-difiuorophenoxy)-l- piperidinyl]ethyl}-3-methoxy-N-methylbenzamide hydrochloride (Compound 18 of Table
I)-
Step a: N- {2-[4-(3,4-Difluorophenoxy)- 1 -piperidinyljethyl} -2,2,2-trifluoroacetamide To a solution of the product of Example 6, Step d (1.5g) and triethylamine (2.45ml) at 0°C in dichloromethane (20ml) was added trifluoroacetic anhydride (1.24ml) dropwise over 10 minutes. After warming to RT the reaction mixture was partitioned between water (20ml) and dichloromethane (20ml). The organic phase was separated and dried with MgSO4. Purification by flash chromatography (dichloromethane: methanol: 98:2)gave the sub-title compound as a colourless oil (1.64g). MS: ESI(+ve) 353(M+H)
1H MR: (299.944 MHz, CDC13) δl.75 - 1.86 (2H, m), 1.93 - 2.02 (2H, m), 2.36 (2H, ddd), 2.58 (2H, t), 2.73 (2H, td), 3.44 (2H, q), 4.25 (IH, m), 6.57 - 6.63 (IH, m), 6.72 (IH, ddd), 6.96 - 7.07 (IH, m), 7.05 (IH, q).
Step b: N- {2-[4-(3,4-Difluorophenoxy)- 1 -piperidinyl] ethyl} -2,2,2-trifluoro-N- methylacetamide
A solution of the product of Step a (1.64g) in THF (5ml) was added dropwise to a suspension of sodium hydride (0.205g 60% suspension in oil) in THF (20ml) at 0°C. The reaction mixture was allowed to warm to RT over 30 min before cooling again to 0°C.
Methyl iodide (0.29ml) in THF (5ml) was added dropwise. The reaction mixture was left stirring at RT for 18 hours before removal of solvents by evaporation. Purification by flash chromatography (dichloromethane: methanol: 880 ΝH3 (aq) 98.5:1 :0.5) gave the title product (0.3 g). MS: ESI(+ve) 367(M+H) Step c: N- {2- [4-(3 ,4-Difluorophenoxy)- 1 -piperidinyl] ethyl } -N-methylamine
To a solution of the product of Step b (0.3g) in ethanol (15ml) was added a 2M solution of sodium hydroxide (5ml). The mixture was stined at RT for 72 hours. The resultant mixture was partitioned between EtOAc (20ml) and water (20ml). The organic layer was separated and dried with MgSO4. Removal of solvent under reduced pressure gave the title compound (0.2g). MS: ESI(+ve) 367(M+H)
1H ΝMR (300 MHz, CDC13) δ 1.74 - 1.84 (2H, m), 1.92 - 2.01 (2H, m), 2.25 - 2.33 (2H, m), 2.46 (3H, s), 2.51 (2H, t), 2.68 - 2.77 (2H, m), 2.68 (2H, t), 4.20 (IH, tt), 6.57 - 6.62 (IH, m), 6.72 (IH, ddd), 7.04 (IH, dt).
Step d: N-{2-[4-(3,4-difluorophenoxy)-l-piperidinyl]ethyl}-3-methoxy-N- methylbenzamide hydrochloride
To a solution of the product of Step c (0.145g) and triethylamine (0.224ml) in THF (3ml) at 0°C was added a solution 3-methoxybenzoyl chloride (0.083ml) in THF (2ml). The mixture was stirred for 1 hour then partitioned between ethyl acetate and water. The organic layer was separated and dried with MgSO and the solvent removed by evaporation. Purification by reverse phase HPLC (with a gradient eluent system 25% MeCΝ/ΝBUOAc(aq) (0.1%) to 95% MeCN//NH OAc(aq) (0.1%)) evaporation of solvent and the residue was dissolved in diethyl ether and HCl (1ml IM solution in diethyl ether) added. Filtration gave the title compound (0.137g). MS: ESI(+ve) 405(M+H)
1H NMR (400 MHz, D2O) δ 1.91 - 2.02 (IH, m), 2.13 (IH, t), 2.30 (IH, d), 2.44 (IH, d), 3.06 (3H, s), 3.24 (IH, t), 3.35 - 3.47 (2H, m), 3.52 (2H, t), 3.65 (IH, d), 3.80 (IH, t), 3.86 (3H, s), 3.97 (2H, t), 6.77 - 6.85 (IH, m), 6.94 - 7.16 (4H, m), 7.20 - 7.27 (IH, m), 7.45 - 7.52 (IH, )
Melting point: 218°C
Example 10 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-3-hydroxybenzamide (Compound 8 of Table II).
Step a: N-{2-[4-(3,4-dicUorophenoxy)-l-piperidmyl]ethyl}-3-methoxybenzamide
The product from Example 3, Step b (2.00g) was dissolved in THF (100ml) and triethylamine (2.10g) added. The solution was then cooled with stirring to 0°C and to it 3- methoxybenzoyl chloride was added dropwise as a solution in THF (lOml). Reaction was left to warm to room temp and left for 24hours then water was added and the organics extracted into ethyl acetate. The combined organics were dried with MgSO4 and the solvent removed by evaporation. The crude product was purified by flash chromatography to leave the sub-title product as a pale yellow oil (1.38g). MS: APCI(+ve): 424 (M+H)
Step b: N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-3-hydroxybenzamide
The product from Step a (1.3g) was dissolved in dichloromethane (40ml) under nitrogen and cooled to -78°C. Boron tribromide was then added slowly and reaction left to warm to room temp and left over 72hours. Methanol was added followed by flash silica (for preabsorption) and purification by flash chromatography (dichloromethane: methanol: 880 ΝH3 (aq) 96.8:4:0.2) to give the title product (l.lg).
1H NMR (300 MHz, CDC13) δ 1.80 - 1.91 (2H, m), 1.97 - 2.09 (2H, m), 2.48 (2H, t), 2.69 (2H, t), 2.80 (2H, t), 3.60 (2H, q), 4.33 (IH, quintet), 6.75 (1H, dd), 6.91 (IH, ddd), 7.00 (IH, d), 7.16 (IH, d), 7.21 (IH, d), 7.31 (IH, d), 7.40 (IH, t).
Example 11 The present Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)- l-piperidinyl]ethyl}-3-[2-(dimethylanrmo)-2-oxoethoxy]bejizamide acetate (a salt of Compound 86 of Table II).
The product from Example 10, Step b (0.150g) was dissolved with 2-chloro-NN- dimethylacetamide (0.045g) in dimethylformamide (10ml) with stirring under nitrogen. Caesium carbonate (0.24 lg) was then added and reaction left for 24hours. Evaporation of solvent and purification by flash chromatography (dichloromethane: methanol: 880 ΝH3 (aq) 96.9:3:0.15) followed by reverse phase HPLC (with a gradient eluent system (25% MeCN/NH4OAcaq (0.1%) to 95% MeCN//NH4OAcaq (0.1%)) gave the product as an acetate salt (0.090g).
MS: APCI(+ve): 494 (M+H)
1H NMR: (299.944 MHz, CDC13) δ 1.74 - 1.88 (2H, m), 1.96 - 2.06 (2H, ), 2.17 (3H, s), 2.38 - 2.47 (2H, m), 2.65 (2H, t), 2.73 - 2.85 (IH, m), 2.99 (3H, s), 3.08 (3H, s), 3.56 (2H, q), 3.98 - 4.13 (IH, ), 4.27 - 4.37 (IH, m), 4.75 (2H,.s), 6.76 (IH, dd), 6.99- 7.04 (2H, m), 7.08 - 7.12 (IH, m), 7.28 - 7.41 (4H, m). Example 12 This Example illustrates the preparation of methyl {3-[({2-[4-(3,4- dichlorophenoxy)- 1 -piperidinyl] ethyl} amino)carbonyl]phenoxy} acetate hydrochloride (a salt of Compound 87 of Table II). To a solution of the product from Example 10, Step b (0.250g) and methyl chloroacetate (0.066g) in dimethylformamide (10ml) under nitrogen was added caesium carbonate (0.4g). The reaction was left to stir for 24hours. Water was added and organics extracted into ethyl acetate and dried with MgSO4. Evaporation of solvent and purification by reverse phase HPLC (with a gradient eluent system 25% MeCN/NH OAcaq (0.1%) to 95% MeCN//NH4OAcaq (0.1 %)) gave the product. The isolated product was then converted to title product by dissolving in diethylether, adding ethereal hydrochloric acid and triturating from diethylether to give the titled product as a white powder (0.050g). MS: APCI(+ve): 481 (M+H)
1H NMR (300 MHz, D2O) δ 1.94 - 2.02 (2H, m), 2.38 - 2.46 (2H, m), 3.25 (2H, t), 3.41 - 3.44 (2H, m), 3.48 (2H, t), 3.56 - 3.66 (2H, m), 3.84 (3H, s), 4.61 - 4.74 (IH, m), 4.88 (2H, s), 6.99 (IH, dd), 7.21 - 7.27 (2H, m), 7.37 - 7.40 (2H, m), 7.49 (2H, t).
Example 13 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-3-(2-hydroxyethoxy)benzamide hydrochloride (a salt of Compound 21 of Table I).
To a solution of the product from Example 10, Step b (0.2g) and 2-(2- bromoethoxy)tetrahydro-2H-pyran (0.209g) in dimethylformamide (10ml) under nitrogen was added caesium carbonate (0.326g). After stirring for 24hours, water was added and organics extracted into ethyl acetate separated and dried with MgSO4. Evaporation of solvent and purification by flash chromatography (eluent 2% MeOH, 0.1% 0.880 ammonia, 97.9% dichloromethane) gave the THP protected titled product. Deprotection of the product was achieved by stirring in trifluoroacetic acid: dichloromethane (1:2) solution (65ml) for 30mins. ΝaHCO3(aq) was added. The product was extracted with ethyl acetate, the combined organic extracts dried with MgSO4 and concentrated to give the crude titled product. Purification by reverse phase HPLC (with a gradient eluent system 25%
MeCN/NIitOAcaq (0.1%) to 95% MeCN/ZNHtOAcaq (0.1%)) was achieved. The isolated product was then converted to title product by dissolving in diethylether, adding ethereal hydrochloric acid and Iriturating from diethylether to give the titled product (0.069g). MS: APCI(+ve): 453 (M+H) lH NMR (400 MHz, DMSO) δ 2.01 - 2.15 (2H,m), 2.27 - 2.34 (2H,m), 3.20 -3.26 (2H,m), 3.32 - 3.41 (2H,m), 3.49- 3.57 (2H,m), 3.69 - 3.90 (4H,m), 4.11 (2H,t), 4.60 - 4.75 (lH,m), 7.05 -7.12 (lH,m), 7.17 (lH,d), 7.41 - 7.47 (2H, m), 7.54 - 7.64 (2H, m) 8.96 (lH,s).
Example 14 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]emyl}-3-[(2-hydroxyemyl)sulfonyl]benzamide acetate (a salt of Compound 22 of Table I). Step a: 3-{[2-(tetrahydro-2J '-pyran-2-yloxy)ethyl]sulfonyl}benzoic acid
To a solution of 3-sulfino-benzoic acid (lg) and 2-iodoethyl tetrahydro-2/J-pyran- 2-yl ether (1.4g) in water (20ml) and ethanol (20ml) was added ΝaOH solution to give a pH of 9. The resulting mixture was refluxed for 3 hours before evaporation of the ethanol. The aqueous was acidified to pH3 and the product extracted with EtOAc. The organic layer was separated, dried with MgSO4 and solvent removed by evaporation to give the sub-title compound (0.25g).
MS: ESI(+ve) 230(M+H - THP)
Step b: N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-3-[(2-hydroxyethyl)- sulfonyljbenzamide acetate
To a solution of the product of Step a (0.20g), the product of Example 3, Step b (0.25g) and diisopropylethyl amine (0.33ml) in dichloromethane (5ml) was added PyBrOP® (0.37g) and the mixture stirred for 24 hours. Purification by Biotage® 40M eluting 20% MeCΝ/2% 880 ammonia/ 78% dichloromethane gave a colourless oil (0.49g) which was dissolved in trifluoroacetic acid (9ml) and water (1ml) and stined for 15 minutes. The solvents were evaporated under reduced pressure and purification by reverse phase HPLC (with a gradient eluent system 25% MeCΝ/ΝH OAcaq (0.1 %) to 95% MeCΝ//ΝH4θAc(aq) (0.1%)) (any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with MgSO and evaporation of solvent) and formation of the acetate salt by dissolving in acetic acid and evaporation of the excess acid gave the title product (0.050g).
MS: ESI(+ve) 501 (M+H) 1H NMR (400 MHz, CDC13) δ 1.79 - 1.87 (2H, m), 1.95 - 2.04 (3H, m), 2.42 (2H, t), 2.65 (2H, t), 2.77 (2H, t), 3.43 (2H, t), 3.58 (2H, q), 3..80 (2H, t), 4.29 - 4.35 (IH, ), 6.76 (IH, dd), 6.92 - 6.97 (IH, m), 7.00 (IH, d), 7.31 (IH, d), 7.65 (IH, t), 8.05 (IH, d), 8.10 (lH, d), 8.30 (lH, t) 5. Example 15
This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-3-[(methylamino)sulfonyl]benzamide acetate (a salt of Compound 9 of Table I).
Prepared in a similar manner to the method of Example 14, Step b using the 0 product from Example 3, Step b and 3-[(methylamino)sulfonyl]benzoic acid to give the title product (0.269g).
MS: ESI(+ve) 486 (M+H)
'H ΝMR (500.076 MHz, DMSO) δ 1.57-1.65 (2H, m), 1.91-1.96 (2H, m), 2.31 (2H, t), 2.43(3H, s), 2.49-2.52 (5H, m), 2.72-2.78 (2H, m), 3.41 (2H, q), 4.45 (IH, m), 6.99 5 (IH, dd), 7.26 (IH, d), 7.50 (IH, d), 7.52-7.58 (IH, m), 7.72 (IH, t), 7.91 (IH, d), 8.09 (IH, d), 8.24(1H, s), 8.69 (IH, t).
Example 16 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidmyl]ethyl}-3-(2-methoxyethoxy)benzamide hydrochloride (A salt of Compound 12 of Table I).
Prepared in a similar manner to the method of Example 14, Step b using the product from Example 3, Step b and 3-(2-methoxyethoxy)benzoic acid to give the title product after formation of a hydrochloride salt (0.213g). MS: ESI(+ve) 467 (M+H) 1H ΝMR: (500.076 MHz, DMSO) δ 1.83 - 1.91 (IH, m), 2.02 - 2.14 (2H, ), 2.22 -
2.31 (IH, m), 3.07 - 3.16 (2H, m), 3.17 - 3.25 (2H, m), 3.32 (3H, s), 3.44 - 3.52 (IH, m), 3.62 - 3.73 (2H, m), 3.68 (2H, t), 4.15 (2H, t), 4.57 - 4.65 (IH, m), 4.81 - 4.85 (IH, ), 7.02 - 7.09 (IH, m), 7.14 (IH, d), 7.35 - 7.38 (IH, m), 7.40 (IH, t), 7.45 - 7.49 (2H, m), 7.56 (IH, t), 8.78 - 8.85 (IH, m). Example 17 This Example illustrates the preparation of tert-butyl 2-{3-[({2-[4-(3,4- dichlorophenoxy)- 1 -piperidinyl]ethyl} amino)carbonyl]phenoxy } ethylcarbamate acetate (a salt of Compound 23 of Table I). Step a: Methyl 3-{2-[(tert-butoxycarbonyl)amino]ethoxy}benzoate
To a solution of tert-butyl 2-bromoethylcarbamate (5g) and methyl 3- hydroxybenzoate (3.4g) in dimethylformamide (60ml) was added caesium carbonate (14.5g) and the reaction stined for 12hours before partitioning between water and ethyl acetate. The organic layer was separated, dried with MgSO4 and the solvent removed by evaporation. Purification by flash chromatography (ethyl acetate: isohexane 92.5:7.5) gave the sub-title product as a colourless oil (3g).
1H NMR (CDC13) δ 1.41 (9H, s), 3.51 (2H, q), 3.87 (3H, s), 4.02 (2H, t), 5.03 - 5.10 (IH, m), 7.05 (IH, ddd), 7.30 (IH, t), 7.50 - 7.51 (IH, m), 7.60 (IH, dt).
Step b: 3-{2-[(tert-butoxycarbonyl)amino]ethoxy}benzoic acid
To a solution of the product of Step a (6g) in THF (120ml) was added lithium hydroxide monohydrate (4.9g) and enough water to ensure full disolution. The reaction was stined for 12 hours, acidified with 2M HCl and partitioned between ethyl acetate and water. The organic layer was separated, dried with MgSO and the solvent removed by evaporation to give the title compound (3.9g).
1H NMR (400 MHz, DMSO) δ 1.38 (9H, s), 3.31 (2H, t), 4.01 (2H, t), 7.02 (IH, t), 7.19 (IH, dt), 7.39 - 7.43 (2H, m), 7.53 (IH, d), 12.97 (IH, s).
Step c: tert-butyl 2- {3-[( {2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl} amino)- carbonyljphenoxy} ethylcarbamate acetate
Prepared in a similar manner to the method of Example 14, Step b using the product from Step b and the product of Example 3, Step b to give the title product
(0.234g).
MS: ESI(+ve) 552 (M+H) 1H NMR: (500.076 MHz, DMSO) δ 1.38 (9H, s), 1.57 - 1.64 (2H, ), 1.89 - 1.94
(2H, ), 1.96 (3H, s), 2.29 (2H, t), 2.47 - 2.51 (6H, m), 2.72 - 2.76 (2H, m), 4.00 (2H, t),
4.43 - 4.46 (IH, m), 6.98 (IH, dd), 7.02 (IH, t), 7.07 - 7.09 (IH, m), 7.26 (IH, d), 7.35 -
7.43 (3H, m), 7.50 (IH, d), 8.39 (IH, t). Example 18 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-3-[(methylsulfonyl)amino]benzamide (Compound 24 of Table I). Step a: 3-amino-N- {2-[4-(3,4-dichlorophenoxy)~ 1 -piperidinyl]ethyl}benzamide Prepared in a similar manner to the method of Example 14, Step b using the product from Example 3, Step b and 3-aminobenzoic acid to give the sub-title product (0.183g).
MS: ESI(+ve) 448 (M+H).
Step b: N-{2-[4-(3,4-dicMorophenoxy)-l-piperidinyl]ethyl}-3-[(methylsulfonyl)amino]- benzamide
To a solution of the product of Step a in pyridine (2ml) was added methanesulfonyl chloride (0.034ml) and the reaction left to stir for 5 mins. Water (0.5ml) was added and the solvents evaporated. Purification by reverse phase HPLC (with a gradient eluent system (25% MeCΝ/ΝH4OAcaq (0.1 %) to 95% MeCN//NH4OAcaq (0.1 %)) (any excess NH OAc was removed by dissolving the compound in dichloromethane and washing with aqueous saturated NaHCO3 followed by drying of the organics with MgSO and evaporation of.solvent) gave the title product (0.091g). MS: APCI (+ve) 486 (M+H) 1H NMR (400 MHz, CDC13) δ 1.80-1.87 (2H, m), 1.96-2.04 (2H, m), 2.38-2.43
(2H, ), 2.64-2.67 (2H, m), 2.79-2.84 (2H, ), 3.02 (3H, s), 3.57-3.62 (2H, m), 4.31-4.32 (IH, m), 6.75-7.90 (9H, m).
Melting point: 150-151°C
Example 19 This Example illustrates the preparation of 3 -(2-aminoethoxy)-N- {2-[4-(3 ,4- dichlorophenoxy)-l-piperidinyl] ethyl} benzamide dihydrochloride (a salt of Compound 25 of Table I).
To a solution of the product of Example 17, Step c (0.163) in dioxane (5ml) was added concentrated HCl (1ml) and the mixture sti ed for 3 hours. The solvents were evaporated and excess HCl removed by azeotroping with toluene. The residue was dissolved in water and after freeze drying gave the title compound (0.145g). MS: ESI(+ve) 452 (M+H). 1H NMR (300 MHz, DMSO) δ 1.96 - 2.10 (2H, m), 2.18 - 2.30 (2H, m), 3.06 - 3.35 (6H, m), 3.42 - 3.50 (IH, m), 3.65 - 3.83 (3H, m), 4.28- (2H, t), 4.58 - 4.70 (IH, m), 4.85 (IH, s), 7.02 - 7.18 (2H, m), 7.33 - 7.45 (2H, m), 7.50 - 7.62 (3H, m), 8.33 (2H, s), 9.04 - 9.11 (lH, m). Example 20
This Example illustrates the preparation of derivatives of (lS)-2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl]- 1 -phenylethylamine Step a: tert-butyl (lS)-2-[4-(3,4-difiuorophenoxy)-l-piperidinyl]-2-oxo-l- phenylethylcarbamate To (2S)-[(tert-butoxycarbonyl)amino](phenyl)ethanoic acid (1 g) in CH C12/DMF
(1:1) (20ml) was added l-ethyl-3-[3-(dimethylamino)-ρropyl]carbodiimide hydrochloride (0.989g) and left to stir for 5 mins. The product of example 6, step b (0.848g) was then added and the reaction left to stir for 24 hrs. Aqueous NaHCO3 solution was added and the product extracted with CH2C12. The organic phase was washed with H2O dried with Na2SO and purification by flash chromatography (ethyl acetate: isohexane 30:70) gave the sub-title compound (0.650g).
MS: ESI(+ve): 447 (M+H)
Step b: (lS)-2-[4-(3,4-difluorophenoxy)-l-piperidinyl]-2-oxo-l-phenylethylarnine The product from Example 20, step a (0.650g) was dissolved in dichloromethane
(7ml) and trifluoroacetic acid (2ml) was added. After 3 hr at room temperature the solution was evaporated and aqueous NaOH (2M) added. The product was extracted with ethyl acetate, the combined organic extracts dried with a2SO4 and concentrated to give the sub-title product as an oil (0.544g). MS: ESI(+ve): 347 (M+H)
Step c: ( 1 S)-2-[4-(3 ,4-difluorophenoxy)- 1 -piperidinyl]- 1 -phenylethylamine
The product from Example 20, step b) (0.544g) was dissolved in THF (5ml) and borane [10.05ml (IM in THF)] was added. The reaction was heated at reflux for 2 hours. The reaction was quenched slowly with MeOH and the solvents evaporated. Aqueous HCl (5ml Concentrated HCl: 5ml H2O) was added and the reaction heated at 70°C for lhour. NaOH (2M) was added until pH 9 was reached. The product was extracted with CH2C12 and the combined organics washed with saturated aqueous NaHCO , dried with Na2SO and solvents evaporated. Purification by flash chromatography (dichloromethane: methanol: 880 NH3 (aq) 89:10:l)gave the sub-title compound as an oil (0.377g). lϋ NMR: (300MHz, CDC13) δ 1.76 (6H, m), 2.20-2.92 (6H, m), 4.08-4.13 (IH, m), 4.18- 4.21 (IH, m), 6.57-7.40 (8H, m).
This compound was then coupled to various acids, using a similar method to that of Example 7, to provide the compounds listed in Table III.
Table III
The compounds of the invention listed in Table III are compounds having the formula below wherein R5 is as defined in the Table.
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000047_0001
Figure imgf000048_0001
Example 21
This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl} -2-[(methylsulfonyl)amino]benzamide hydrochloride. Step a: 2-amino-N- {2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyl] ethyl } benzamide dihydrochloride.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b.
MS: APCI(+ve): 408(M+H).
1H NMR (399.98 MHz, DMSO) δ 1.91 - 1.98 (2H, m), 2.15 - 2.26 (2H, m), 2.58 (2H, m), 3.18-3.29 (3H, m), 3.36 (2H, t), 3.57-3.68(2H, m), 3.72-3.79 (2H, m), 4.66 (IH, s), 6.63-6.71 (2H, m), 6.83 (IH, dd), 7.06 (IH, d), 7.22(1H, dt), 7.51 (IH, dd), 7.90 (IH, s). Step b: N-{2-[4-(3,4-dichlorophenoxy)-l-piperid yl]emyl}-2-[(memylsulfonyl)amino]- benzamide hydrochloride.
Prepared in a similar manner to Example 18, Step b. MS: APCI(+ve): 486(M+H) 1HNMR(399.98 MHz, CDCL3) δ 1.82(2H, m), 2.00(2H, m), 2.39(2H, m), 2.63(2H, t), 2.65(2H, m), 3.05(3H, s), 3.52(2H, q), 4.31(1H, m), 6.76(1H, dd), 7.00(1H, m), 7.15(1H, m), 7.32(1H, d), 7.50(2H, m), 7.73(1H, dt)
Example 22 This Example illustrates the preparation of 3-(aminosulfonyl)-N-{2-[4-(3,4- dichlorophenoxy)-l-piperidinyl]ethyl}benzamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 472 (M+H)
1H NMR (399.98 MHz, DMSO) δ 1.57 - 1.65 (2H, m), 1.91 - 1.94 (2H, m), 2.27 - 2.33 (2H, m), 2.48 - 2.52 (2H, m), 2.73 - 2.75 (2H, m), 3.40 (2H, q), 4.45 (IH, m), 6.98 (IH, dd), 7.26 (IH, d), 7.49 (3H, d), 7.67 (IH, t), 7.96 (IH, ddt), 8.03 (IH, tdt), 8.30 (IH, t), 8.65 (IH, t)
Melting point: 168-169°C
Example 23 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl] ethyl } - 1 -ethyl-7-methyl-4-oxo- 1 ,4-dihydro [ 1 , 8]naphthyridine-3 -carboxamide. Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 503 (M+H)
1H NMR (299.946 MHz, DMSO) δ 1.25 - 1.68 (5H, m), 1.72 - 1.81 (2H, m), 1.88 - 1.95 (2H, m), 2.22 (3H, s), 2.31 - 2.40 (2H, m), 2.60 - 2.78 (3H, ), 2.92 - 3.00 (IH, ), 3.44 - 3.52 (IH, m), 4.36 - 4.49 (2H, m), 5.92 - 6.11 (IH, m), 6.91 - 7.06 (IH, m), 7.25 (IH, s), 7.30 - 7.41 (IH, m), 7.44 - 7.54 (IH, m), 11.86 (IH, s). Melting point: 169-171°C
Example 24 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-2-(4-hydroxyphenyl)acetamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve):423 (M+H) 1H NMR (399.98 MHz, DMSO) δ 1.53 - 1.61 (2H, ), 1.84 - 1.91 (2H, m), 2.17 - 2.24 (2H, m), 2.29 - 2.37 (2H, m), 2.60 - 2.70 (2H, m), 3.09 - 3.18 (2H, m), 3.28 (2H, s), 4.36 - 4.46 (IH, m), 6.62 - 6.72 (2H, m), 6.93 - 7.00 (IH, m), 7.00 - 7.08 (2H, m), 7.21 - 7.27 (1H, m), 7.43 - 7.53 (IH, m), 7.73 - 7.83 (IH, m), 9.25 (IH, s). Example 25
This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyljethyl} -2-[5-(l -pynolidinyl)-2H-tetraazol-2-yl]acetamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 468 (M+H) 1H NMR (399.98 MHz, DMSO) δ 1.56 - 1.63 (2H, m), 1.88 - 1.95 (6H, m), 2.22 -
2.27 (2H, m), 2.37 - 2.42 (2H, m), 2.65 - 2.72 (2H, m), 3.20 - 3.24 (2H, m), 3.31 - 3.37 (4H, m), 4.40 - 4.47 (IH, m), 5.19 (2H, s), 6.96 - 7.01 (IH, m), 7.24 - 7.27 (IH, m), 7.50 (lH, d), 8.15 - 8.24 (lH, m).
Melting point: 114-116°C Example 26
This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-2-(2-memyl-4-phenyl-l,3-thiazol-5-yl)acetamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b.
MS: APCI(+ve): 504 (M+H) 1H NMR (299.946 MHz, DMSO ) δ 1.54 - 1.63 (2H, m), 1.85 - 1.93 (2H, m), 2.21 ■
2.28 (2H, m), 2.33 - 2.39 (2H, m), 2.62 - 2.71 (5H, m), 3.16 - 3.22 (2H, m), 3.74 (2H, s), 4.39 - 4.48 (IH, m), 6.94 - 7.00 (IH, m), 7.23 - 7.27 (IH, m), 7.34 - 7.50 (4H, m), 7.60 - 7.67 (2H, m), 8.08 - 8.15 (IH, m).
Example 27 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidmyl]ethyl}-5-(methylsulfonyl)-2-tMophenecarboxamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 477 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.54 - 1.65 (2H, m), 1.87 - 1.96 (2H, m), 2.24 - 2.34 (2H, m), 2.68 - 2.77 (2H, m), 3.34 - 3.42 (8H, m), 4.35 - 4.49 (IH, m), 7.25 (IH, d), 7.49 (IH, d), 7.81 (2H, t), 8.80 (IH, t) Melting point: 142-143°C Example 28 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}-6-(lH-ρyrazol-l-yl)nicotinamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve):460 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.54 - 1.69 (2H, m), 1.85 - 2.00 (2H, m), 2.23 - 2.37 (3H, m), 2.68 - 2.81 (2H, m), 3.34 - 3.47 (3H, m), 4.41 - 4.49 (IH, m), 6.60 - 6.64 (IH, m), 6.93 - 7.04 (IH, m), 7.26 (IH, d), 7.46 - 7.55 (IH, m), 7.89 (IH, d), 7.95 - 8.05 (IH, m), 8.32 - 8.42 (IH, ), 8.60 - 8.71 (2H, m), 8.85 - 8.92 (IH, m) Melting point: 154- 155°C
Example 29 This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl} -4-(methylsulfonyl)benzamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 471 (M+H)
XH NMR: (399.98 MHz DMSO) δ 1.55 - 1.67 (2H, m), 1.86 - 1.97 (2H, m), 2.24 - 2.35 (2H, m), 2.69 - 2.79 (2H, m), 3.35 - 3.46 (7H, m), 4.39 - 4.49 (IH, m), 6.94 - 7.03 (IH, m), 7.25 (IH, d), 7.49 (IH, d), 7.99 - 8.10 (4H, m), 8.66 (IH, t) Melting point: 100- 101 °C Example 30
This Example illustrates the preparation of N-{2-[4-(3,4-dichlorophenoxy)-l- piperidinyl]ethyl}imidazo[l,2-a]pyridine-2 -carboxamide.
Prepared in a similar manner to Example 7 using the product of Example 3, Step b. MS: APCI(+ve): 433 (M+H) 1H NMR: (399.98 MHz DMSO) δ 1.53 - 1.70 (2H, m), 1.86 - 2.00 (2H, m), 2.23 -
2.34 (2H, m), 2.66 - 2.80 (2H, m), 3.27 - 3.35 (2H, m), 3.34 - 3.46 (2H, m), 4.41 - 4.50 (IH, m), 6.94 - 7.02 (2H, m), 7.26 (IH, d), 7.29 - 7.39 (IH, m), 7.46 - 7.53 (IH, m), 7.56 - 7.63 (IH, m), 8.22 (IH, t), 8.35 (IH, s), 8.52 - 8.67 (IH, ) Melting point: 150-151°C Example 31 This Example illustrates the preparation of 5-(2-chloroanilino)-N-{2-[4-(3,4- dichlorophenoxy)- 1 -ρiperidinyl]ethyl}-l ,3,4-oxadiazole-2 -carboxamide. Step a: N-{2-[4-(3,4-dichlorophenoxy)piperidin-l-yl]ethyl}-2-hydrazino-2-oxoacetamide. To a solution of the product of Example 3, Step b (0.85g) and triethylamine
(0.82ml) at RT in dichloromethane (20ml) was added methyl oxalyl chloride (0.30ml) dropwise over 10 minutes. The reaction mixture was partitioned between water (20ml) and dichloromethane (20ml). The organic phase was separated and dried with MgSO . Evaporation under reduced pressure gave an oil which was dissolved in ethanol (10ml) at RT and treated with hydrazine hydrate (1 l) The reaction mixture was stined at reflux for 24 hours, filtered and the filtrate evaporated under reduced pressure to leave an oil. Purification by flash chromatography (dichloromethane: methanol 90:10)gave the sub-title compound as a white solid (0.18g). MS: ESI(+ve): 375 (M+H)
Step b: 5-(2-chloroamiino)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-l,3,4- oxadiazole-2 -carboxamide.
2-Chlorophenylisothiocyanate (0.102g) was added to a stined suspension of the compound from Step a (0.18g) in dimethylformamide (5ml) stirring at RT. After stirring for 1 hour, aminomethylated polystyrene (0.295g) was added and the mixture stined at RT for 16 hours. N-Cyclohexylcarbodiimide, andN'-methyl polystyrene (0.57g) was then added and the mixture stirred at 80°C for 2 hours. The reaction mixture was cooled to RT, filtered, and the resin washed with dimetnylformamide (3 x 5ml). The combined filtrates were evaporated and the residue triturated with diethyl ether, filtration gave the title compound as a white solid (0.14g). MS: APCI(+ve): 510 (M+H)
1H NMR: (299.98 MHz DMSO) δ 1.51 - 1.70 (2H, m), 1.83 - 1.98 (2H, m), 2.19 - 2.37 (2H, m), 2.42 - 2.55 (IH, m), 2.63 - 2.81 (2H, m), 3.23 - 3.49 (3H, m), 4.32 - 4.53 (IH, ), 6.89 - 7.61 (6H, m), 7.88 - 8.01 (IH, m), 8.80 - 8.99 (IH, m), 10.32 (IH, s) Melting point: 161-162°C Example 32 This Example illustrates the preparation of N-{2.-[4-(2-chloro-4-fluorophenoxy)-l- piperidinyl] ethyl} -6-( 1 H-p yrazol- 1 -yl)nicotinamide. Step a: 4-(2-C oro-4-fluorophenoxy)piperidine. DEAD (0.90ml) was added to a solution of triphenylphosphine (1.44g), 2-chloro-4- fluorophenol (0.806g) and 4-hydroxy-piperidine-l-carboxylic acid tert-butyl ester(l.Og) in THF at RT. The reaction was stined for 16hrs, HCl (2ml, 4M in dioxan) added and the mixture stirred at RT for 16 hrs. The mixture was then evaporated to dryness, triethylamine (5ml) added, re-evaporated, dissolved in methanol (10ml) and placed on to a SCX cartridge (Narian, lOg), eluted first with methanol then with 10%ΝH3 in methanol. The basic fractions were combined and evaporated to give the sub-title compound as an oil (0.98g) MS: ESI(+ve): 230 (M+H)).
Step b: 2-[4-(2-Chloro-4-fluorophenoxy)piperidin-l-yl]ethylamine.
Potassium carbonate (1.02g, 0.0074 mol) was added to a solution of the 2-chloro-4- fluorophenoxypiperidine (1.7g, 0.0074 mol) and tert-butyl 2-bromoethylcarbamate (1.65g, 0.0074 mol) strirring at RT. The resulting mixture was stined at RT for 24 hours, diluted with ethyl acetate (200ml) and washed with saturated brine solution (3 x 100ml). The organic layer was dried with MgSO and evaporated under reduced pressure. The residual oil was redissolved in dichloromethane (200ml), treated with TFA (20ml) and the solution stirred at RT overnight, evaporation under reduced pressure and purification by flash chromatography (ethyl acetate) gave the sub-title compound as a colourless oil (l.lg). MS: ESI(+ve): 273 (M+H)).
Step c: N-{2-[4-(2-Chloro-4-fluorophenoxy)-l-piperidinyl]ethyl}-6-(lH-pyrazol-l- yl)nicotinamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 32, step b. MS: APCI(+ve): 444 (M+H)
1H NMR: (299.98 MHz DMSO) δ 1.48 - 1.77 (2H, m), 1.79 - 1.99 (2H, m), 2.22 - 2.41 (2H, ), 2.45 - 2.57 (2H, ), 2.62 - 2.81 (2H, m), 3.37 - 3.50 (2H, m), 4.33 - 4.50 (IH, m), 6.53 - 6.66 (IH, m), 7.01 - 7.28 (2H, m), 7.33 - 7.47 (IH, m), 7.81 - 7.94 (IH, m), 7.94 - 8.08 (IH, m), 8.30 - 8.43 (IH, m), 8.56 - 8.74 (2H, m), 8.83 - 8.96 (IH, m) ' Melting point: 109-110°C
Example 33 This Example illustrates the preparation of N- {2-[4-(2-chloro-4-fiuorophenoxy)- 1 - piperidinyl]ethyl}-3-(methylsulfonyl)benzamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 32, step b.
MS: APCI(+ve): 455 (M+H) 1H NMR: (299.946 MHz DMSO) δ 1.60 - 1.78 (2H, m), 1.83 - 1.98 (2H, m), 2.24 -
2.40 (2H, m), 2.66 - 2.75 (2H, m), 2.94 - 3.06 (IH, m), 3.28 - 3.33 (2H, m), 3.37 - 3.47 (4H, m), 4.36 - 4.50 (IH, ), 7.10 - 7.28 (2H, m), 7.37 - 7.46 (IH, ), 7.67 - 7.82 (IH, m), 8.03 - 8.11 (IH, m), 8.14 - 8.20 (IH, m), 8.33 - 8.39 (IH, m), 8.67 - 8.76 (IH, m) Melting point: 50-51°C Example 34
This Example illustrates the preparation of N-{2-[4-(2,4-dichloro-3- methylphenoxy)-l-piperidmyl]ethyl}-4-(memylsulfonyl)benzamide. Step a: 4-(2,4-Dichloro-3-methylphenoxy)piperidine.-
The sub-titled compound was prepared in a similar manner to Example 32, Step a. MS: ESI(+ve): 260 (M+H)
Step b: 2- [4-(2,4-Dichloro-3 -methylphenoxy)piperidin- 1 -yl] ethylamine.
The sub-titled compound was prepared in a similar manner to Example 32, Step b.
MS: ESI(+ve): 303 (M+H)
Step c: N-{2-[4-(2,4-DicUoro-3-methylphenoxy)-l-piperidinyl]ethyl}-4- (methylsulfonyl)benzamide.
The sub-titled compound was prepared in a similar manner to Example 7 using the product of Example 34, Step b. MS: APCI(+ve): 485 (M+H)
1H NMR: (299.98 MHz DMSO) δ 1.57 - 1.73 (2H, m), 1.81 - 1.99 (2H, m), 2.25 - 2.40 (6H, m), 2.61 - 2.80 (2H, m), 3.16 - 3 2 (6H, m), 4.37 - 4.56 (IH, m), 7.02 - 7.16 (IH, m), 7.26 - 7.41 (IH, ), 7.95 - 8.13 (4H, m), 8.57 - 8.74 (IH, m) Melting point: 171 - 172°C
Example 35 This Example illustrates the preparation of N-{2-[4-(2,4-dichloro-3- methylphenoxy)-l-piperidmyl]ethyl}-5-(methylsulfonyl)-2-t ophenecarboxamide. The title compound was prepared in a similar manner to Example 7 using the product of Example 34, step b.
MS: APCI(+ve): 491 (M+H)
1H NMR: (299.98 MHz DMSO) δ 1.50 - 1.77 (2H, m), 1.79 - 2.05 (2H, ), 2.23 - 2.58 (6H, m), 2.60 - 2.81 (2H, m), 3.22 - 3.47 (6H, m), 4.35 - 4.65 (IH, m), 7.01 - 7.18 (IH, m), 7.26 - 7.44 (IH, m), 7.71 - 7.91 (2H, m), 8.68 - 8.91 (IH, m) Melting point: 177- 178°C
Example 36 This Example illustrates the preparation of N-{2-[4-(2,4-dichloro-3- metnylphenoxy)-l-piperidinyl]ethyl}-2-(methylsulfonyl)benzamide. The title compound was prepared in a similar manner to Example 7 using the product of Example 34, step b.
MS: APCI(+ve): 485 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.59 - 1.73 (2H, m), 1.84 - 1.99 (2H, m), 2.29 - 2.43 (6H, m), 2.62 - 2.79 (2H, m), 3.24 - 3.43 (6H, m), 4.42 - 4.61 (IH, m), 7.00 - 7.17 ' (IH, m), 7.28 -7.43 (IH, m), 7.45 - 7.60 (IH, m), 7.64 - 7.83 (2H, m), 7.89 - 8.04 (IH, m), 8.53 (lH, t)
Melting point: 71-72°C
Example 37 This Example illustrates the preparation of N-{2-[4-(4-chloro-3-methylphenoxy)-l- piperidinyl] ethyl } -4-(methylsulfonyl)benzamide. Step a: 4-(4-Chloro-3-methylphenoxy)piperidine.
The sub-titled compound was prepared in a similar manner to Example 32, Step a. MS: ESI(+ve): 226 (M+H)
Step b: 2-[4-(4-CMoro-3-me ylphenoxy)piperidm-l-yl]ethylamine.
The sub-titled compound was prepared in a similar manner to Example 32, Step b. MS: ESI(+ve): 269 (M+H) Step c: N- {2-[4-(4-Chloro-3-methylphenoxy)- 1 -piperidinyl]ethyl} -4- (methylsulfonyl)benzamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 37, Step b. MS : APCI(+ve): 451 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.53 - 1.67 (2H, ), 1.89 - 1.98 (2H, m), 2.23 -
2.32 (5H, m), 2.67 - 2.83 (2H, m), 3.22 - 3.34 (7H, m), 4.29 - 4.40 (IH, m), 6.74 - 6.84 (IH, m), 6.96 (IH, d), 7.26 (IH, d), 7.97 - 8.11 (4H, m), 8.66 (IH, t)
Melting point: 123-124°C Example 38
This Example illustrates the preparation of N-{2-[4-(4-chloro-3-methylphenoxy)-l- piperidinyl]ethyl}-6-(lH-pyrazol-l-yl)nicotinamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 37, Step b. MS: APCI(+ve): 440 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.55 - 1.67 (2H, m), 1.83 - 2.03 (2H, m), 2.20 - 2.35 (6H, m), 2.69 - 2.87 (2H, m), 3.27 - 3.34 (IH, m), 3.36 - 3.50 (2H, m), 4.29 - 4.42 (IH, m), 6.55 - 6.67 (IH, m), 6.73 - 6.88 (IH, m), 6.96 (IH, d), 7.26 (IH, d), 7.89 (IH, d), 7.94 - 8.06 (IH, m), 8.29 - 8.42 (IH, m), 8.58 - 8.74 (2H, m), 8.80 - 8.94 (IH, m) Melting point: 183-184°C
Example 39 This Example illustrates the preparation of N-{2-[4-(4-chloro-3-methylphenoxy)-l- piperidinyl]etiιyl}-2-(methylsulfonyl)benzamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 37, Step b.
MS: APCI(+ve): 451 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.52 - 1.68 (2H, m), 1.83 - 2.00 (2H, m), 2.20 -
2.33 (5H, m), 2.68 - 2.79 (2H, m), 3.27 - 3.40 (7H, m), 4.30 - 4.42 (IH, m), 6.77 - 6.85 (IH, m), 6.92 - 6.99 (IH, m), 7.22 - 7.31 (IH, ), 7.48 - 7.56 (IH, m), 7.64 - 7.82 (2H, m), 7.93 - 8.00 (IH, m), 8.49 - 8.64 (IH, m) Melting point: 63-64°C Example 40 This Example illustrates the preparation of 3-(aminosulfonyl)-4-chloro-N-{2-[4- (3,4-difluoroρhenoxy)- 1 -piperidinyl]ethyl}benzamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
MS: APCI(+ve): 474 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.54 - 1.65 (2H, m), 1.86 - 1.97 (2H, m), 2.22 - 2.35' (2H, m), 2.64 - 2.82 (2H, ), 3.36 - 3.43 (2H, m), 4.29 - 4.41 (IH, ), 6.73 - 6.83 (IH, ), 7.03 - 7.14 (IH, m), 7.24 - 7.38 (IH, m), 7.70 (2H, s), 7.73 - 7.80 (3H, ), 7.98 - 8.06 (IH, m), 8.44 (IH, d), 8.68 - 8.75 (IH, m) Melting point: 80-81°C
Example 41 This Example illustrates the preparation of 2-cyano-N-{2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl]ethyl}benzamide. The title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
MS: APCI(+ve): 386 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.46 - 1.58 (2H, m), 1.78 - 1.94 (2H, m), 2.22 - 2.35 (2H, m), 2.54 - 2.63 (2H, ), 2.70 - 2.83 (2H, m), 3.79 - 3.89 (2H, m), 4.28 - 4.39 (IH, m), 6.72 - 6.81 (IH, m), 7.00 - 7.14 (IH, m), 7.23 - 7.37 (IH, m), 7.65 - 7.84 (3H, ), 8.15 (lH, d), 10.11 (lH, d)
Melting point: 146-147°C
Example 42 This Example illustrates the preparation of 2-chloro-N-{2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl]ethyl} -4-(methylsulfonyl)benzamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
MS: APCI(+ve): 473 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.55 - 1.65 (2H, m), 1.88 - 1.97 (2H, m), 2.24 - 2.34 (2H, m), 2.69 - 2.79 (2H, m), 3.34 - 3.43 (7H, m), 4.31 - 4.42 (IH, m), 6.74 - 6.82 (IH, m), 7.03 - 7.16 (IH, m), 7.25 - 7.38 (IH, m), 7.68 (IH, t), 7.90 - 7.96 (IH, m), 8.04 (lH, d), 8.56 (lH, t)
Melting point: 108-109°C Example 43 This Exampleillustrates the preparation of 3-cyano-N-{2-[4-(3,4- difluorophenoxy)- 1 -piperidinyl] ethyl } benzamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
MS: APCI(+ve): 386 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.54 - 1.65 (2H, m), 1.86 - 1.98 (2H, m), 2.22 - 2.34 (2H, m), 2.69 - 2.79 (2H, m), 3.35 - 3.45 (4H, m), 4.32 - 4.40 (IH, m), 6.74 - 6.81 (IH, m), 7.04 - 7.14 (IH, m), 7.25 - 7.37 (IH, m), 7.65 - 7.73 (IH, m), 7.97 - 8.03 (IH, m), 8.10 - 8.16 (IH, m), 8.25 (IH, t), 8.63 (IH, t) Melting point: 106-107°C
Example 44 This Example illustrates the preparation of N-{2-[4-(3,4-difluorophenoxy)-l- piperidinyl] ethyl } -4- [(methy lsulfony l)methyl]b enzamide. The title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
MS: APCI(+ve): 453 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.52 - 1.66 (2H, m), 1.69 - 1.77 (2H, m), 1.86 - 1.99 (2H, m), 2.22 - 2.33 (2H, m), 2.69 - 2.79 (2H, m), 2.88 - 2.95 (3H, m), 2.97 - 3.07 (2H, m), 4.29 - 4.41 (IH, m), 4.55 (2H, s), 6.69 - 6.86 (IH, m), 7.01 - 7.16 (IH, m), 7.22 - 7.36 (IH, m), 7.49 (2H, d), 7.84 (2H, d), 8.42 (IH, t) Melting point: 115-116°C
Example 45 This Example illustrates the preparation of N-{2-[4-(3,4-difluorophenoxy)-l- piperidinyl] ethyl } -6-( 1 H-pyrazol- 1 -yl)mcotinamide.
The title compound was prepared in a similar manner to Example 7 using the product of Example 6, Step d.
MS: APCI(+ve): 428 (M+H)
1H NMR: (399.98 MHz DMSO) δ 1.50 - 1.68 (2H, m), 1.83 - 2.01 (2H, m), 2.20 - 2.36 (2H, m), 2.69 - 2.83 (2H, m), 3.36 - 3.50 (4H, m), 4.28 - 4.45 (IH, m), 6.56 - 6.66 (IH, m), 6.73 - 6.83 (IH, ), 7.02 - 7.15 (IH, m), 7.25 - 7.38 (IH, m), 7.89 (IH, d), 7.96 - 8.06 (IH, m), 8.33 - 8.41 (IH, m), 8.60 - 8.73 (2H, m), 8.84 - 8.93 (IH, m) Melting point. 161-162°C Example 46
Pharmacological Analysis: Calcium flux [Ca 2+]i assay Human eosinophils
Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., J. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended (5x10° ml'1) and loaded with 5μM FLUO-3/AM + Pluronic F127
2.2μl/ml (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO4
0.8mM, glucose 5.5mM, Na2CO3 8.5mM, KC1 5mM, HEPES 20mM, CaCl2 1.8mM, BSA
0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at 2.5xl06 ml"1. The cells were then transfened to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with 5μM fibronectin for two hours) at 25μl/well. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS (200μl; room temperature).
A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1 %(v/v) DMSO. Assays were initiated by the addition of an A50 concentration of eotaxin and the transient increase in fluo-3 fluorescence (1EX =490nm and lEm = 520nm) monitored using a FLIPR (Fluorometric imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).
Human eosinophil chemotaxis Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., J. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended at lOxlO6 ml"1 in RPMI containing 200 IU/ml penicillin, 200 μg/ml streptomycin sulphate and supplemented with 10% HIFCS, at room temperature.
Eosinophils (700 μl) were pre-incubated for 15 mins at 37° C with 7 μl of either vehicle or compound (lOOx required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, 3μm pore, Neuroprobe) was loaded by adding 28μl of a concentration of eotaxin (0.1 to lOOnM) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and 25 μl of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO2 atmosphere to allow chemotaxis.
The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 rnins at room temperature) and the filter removed and the supernatant transfened to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 μl of PBS containing 0.5% Triton xl 00 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils nήgrating was quantified according to the method of Strath et al., J. Immunol Methods, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.
Certain compounds of the Examples were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis.
Example 47 Guinea-pig isolated trachea
(See for example, Harrison, R.W.S., Carswell, H. & Young, J.M. (1984) European J. Pharmacol, 106, 405-409.) Male albino Dunkin-Hartley guinea-pigs (250g) were killed by cervical dislocation and the whole trachea removed. After clearing the adherent connective tissue, the trachea was cut into six ring segments each three cartilage bands wide and then suspended in 20ml organ baths containing Krebs-Henseleit solution of the following composition (mM): NaCl 117.6, NaH2PO 0.9, NaHCO3 25.0, MgSO 1.2, KC1 5.4, CaCl2 2.6 and glucose 11.1. The buffer was maintained at 37°C and gassed with 5% CO2 in oxygen. Indomethacin (2.8μM) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo- oxygenase products. The tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders. Experimental protocols
At the beginning of each experiment a force of lg was applied to the tissues and this was reinstated over a 60 minute equilibration period until a steady resting tone was achieved. Subsequently, a cumulative histamine concentration effect (E/[A]) curve was constructed at 0.5 log10 unit increments, in each tissue. The tissues were then washed and approximately 30 minutes later, test compound or vehicle (20% DMSO) was added. Following an incubation period of 60 minutes a second E/[A] curve was performed to Mstamine.
Contraction responses were recorded as a percentage of the first curve maximum. Data analysis
Experimental E/[A] curve data were analysed for the purposes of estimating the potencies (p[A50] values) of histamine in the absence and presence of the test compound. Affinity (pA2) values of test compounds were subsequently calculated using the following equation: log(r-l) = log[B] + pA2 where r = [A]50 in presence of test comρound/[A]5o in absence of antagonist and [B] is the concentration of test compound. Compounds were found to be HI antagonists.

Claims

A compound of formula (I):
Figure imgf000062_0001
wherein
R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(C1-6 haloalkyl), halogen, C1-6 alkyl, C1-6 haloalkyl or C1-6 alkoxy; n is 0, 1, 2, 3 or 4; m is 0 or 1; when m is 0 then q is 0, and when m is 1 then q is 1, 2 or 3; provided that n + m + q = 1, 2, 3 or 4; when R2 and R3 are, independently, hydrogen or C1- alkyl, and R4 is hydrogen, then R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted at least once with a substituent selected from the group comprising: C1-6 alkyl (substituted with NH2, CO (C1-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(Cj-6 alkyl), NHS(O)2(C1-6 alkyl), C1-6 alkoxy (substituted with C1-6 alkoxy, hydroxy, CO2(C1-6 alkyl), NHC(O)O(C1-6 alkyl) or NH2), C2-6 alkenyl, pynolyl and Δ3-pynolinyl; and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 haloalkyl, Cι-6 haloalkoxy, NR R , C3-6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylthio(C1-6 alkyl), C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, and C(O)R10- substituted C1-6 alkyl or C1-6 alkoxy groups; when R2 and R3 are, independently, hydrogen or C1- alkyl, and R4 is C^ alkyl or C3-6 cyclo l y^C alkyl), then R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, C1-6 alkyl (optionally substituted with halogen, C1-6 alkylthio, NH2, C(O)R10, CO2(Cι-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), C3-6 cycloalkyl, Cι-6 alkoxy (substituted with halogen, Cι-6 alkoxy, hydroxy, C(O)R10, CO2(C1-6 alkyl), NHC(O)O(C1-6 alkyl) or NH2), C2-6 alkenyl, . 6 alkoxycarbonyl, NR6R7, C3- cycloalkylamino, C1-6 alkylthio, C1- alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(Cι-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(Cι-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or Δ3- pynolinyl; and when R2 is phenyl (optionally substituted with halogen, C1-4 alkyl or C1- alkoxy), R3 is hydrogen or C1-6 alkyl, and R4 is hydrogen, C1- alkyl or C3-6 cycloalkyl(C1- alkyl), then R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, C1-6 alkyl (optionally substituted with halogen, Cι_6 alkylthio, NH2, C(O)R10, CO2(C1-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O) NR13R14), C3-6 cycloalkyl, C1-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(C1-6 alkyl), NHC(O)O(C1-6 alkyl) or NH2), C2-6 alkenyl, . β alkoxycarbonyl, NR6R7, C3-6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(Cι_6 alkyl), S(O)2(Cι-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or Δ3- pyrrolinyl;
R10 is hydroxy or NRπR12 group; and,
R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or C1-6 alkyl; or a pharmaceutically acceptable salt thereof; or a solvate thereof.
2. A compound of formula (I) as claimed in claim 1 wherein R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(Cι-6 haloalkyl), halogen, C1-6 alkyl, Ci-6 haloalkyl or C1-6 alkoxy; n is 0, 1, 2, 3 or 4; m is 0 or 1; when m is 0 then q is 0, and when m is 1 then q is 1, 2 or 3; provided that n + m + q = 1, 2, 3 or 4; R2 and R3 are, independently, hydrogen or Cι-6 alkyl; R4 is hydrogen; R3 is a 3- to 10- membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted at least once with a substituent selected from the group comprising: C1-6 alkyl (substituted with NH2, CO2(Cι-6 alkyl), S(O)2(Cι-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), S(O)2(C1-6 alkyl), S(O)2(Cι-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), C1-6 alkoxy (substituted with d-6 alkoxy, hydroxy, CO2(C1-6 alkyl), NHC(O)O(Cι-6 alkyl) or
NH2), C2-6 alkenyl, pynolyl and Δ3 -pynolinyl; and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, Cj_6 haloalkyl, C1-6 haloalkoxy, NR R , C3..6 cycloalkylamino, C1- alkylthio, C1-6 . alkylthio(C1-6 alkyl), C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido
(S(O)2NH2), (di)C1-6 alkylsulphonamido, phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, and C(O)R10-substituted C1-6 alkyl or C1-6 alkoxy groups; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9,
R11, R12, R13 and R14 are independently hydrogen or C1-6 alkyl.
3. A compound of formula (I) as claimed in claim 1 wherein R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(C1-6 haloalkyl), halogen, Cι_6 alkyl, C1-6 haloalkyl or -6 alkoxy; n is 0, 1, 2, 3 or 4; m is 0 or 1; when m is 0 then q is 0, and when m is 1 then q is 1, 2 or 3; provided that n + m + q = 1, 2, 3 or 4; R2 and R3 are, independently, hydrogen or Cι-6 alkyl; R4 is C1-4 alkyl or C3-6 cycloalky^ -
4 alkyl); R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, Cι-6 alkyl (optionally substituted with halogen, Cι-6 alkylthio, NH2,
C(O)R10, CO2(C1-6 alkyl), S(O)2(C1-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), C3-6 cycloalkyl, Cι-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(C1-6 alkyl), NHC(O)O(C1-6 alkyl) orNH2), C2-6 alkenyl, C1-6 alkoxycarbonyl, NR6R7, C3-6 cycloalkylamino, C1-6 alkylthio, C^ alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 all yl), NHC(O)(C1-6 alkyl), NHS(O)2(C1-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pynolyl or ΔJ- pynolinyl; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or C1-6 alkyl.
4. A compound of formula (I) as claimed in claim 1 wherein R1 is phenyl optionally substituted by cyano, S(O)2(C1-6 alkyl), S(O)2(Cι-6 haloalkyl), halogen, C1-6 alkyl,
C1-6 haloalkyl or C1-6 alkoxy; n is 0, 1 , 2, 3 or 4; m is 1 ; q is 1 ; provided that n + m + q = 2, 3 or 4; R2 is phenyl (optionally substituted with halogen, Cμ alkyl or C1-4 alkoxy); R3 is hydrogen or C1-6 alkyl; R4 is hydrogen, C1- alkyl or C3-6 cycloalkyl(C1-4 alkyl); R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, cyano, nitro, hydroxy, C1-6 alkyl (optionally substituted with halogen, C1-6 alkylthio, NH2, C(O)R10, CO2(C1-6 alkyl), S(O)2(CI-6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), C3.6 cycloalkyl, C1-6 alkoxy (substituted with halogen, C1-6 alkoxy, hydroxy, C(O)R10, CO2(Cι.6 alkyl), NHC(O)O(C1-6 alkyl) or NH2), C2-6 alkenyl, . β alkoxycarbonyl, NR6R7, C3- cycloalkylamino, C1-6 alkylthio, .6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido, S(O)2(C1-6 alkyl), S(O)2(C1-6 hydroxyalkyl), S(O)2NH(C1-6 alkyl), NHC(O)(Cι-6 alkyl), NHS(O)2(C1-6 alkyl), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, furanyl, pyrrolyl or Δ3- pynolinyl; R10 is hydroxy or NRπR12 group; and, R6, R7 R8, R9, R11, R12, R13 and R14 are independently hydrogen or Cι-6 alkyl.
5. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein m and q are both 0.
6. A compound of formula (I) as claimed in claim 1, 2, 3, 4 or 5 wherein R1 is phenyl optionally substituted by halogen, C1- alkyl or C1- alkoxy.
7. A compound of formula (I) as claimed in claim 1, 2, 3, 4, 5 or 6 wherein n is 2.
8. A compound of formula (I) as claimed in claim 1, 2, 3, 4, 5, 6 or 7 wherein R4 is hydrogen or CM alkyl; and R5 is a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being substituted by at least one of Ci.6 alkyl (substituted with S(O)2(Cι.6 alkyl), NHS(O)2(C1-6 alkyl) or S(O)2NR13R14), S(O)2(Cι-6 alkyl), S(O)2NH(C1-6 alkyl), NHC(O)(C1-6 alkyl) or
NHS(O)2(C1-6 alkyl); and optionally further substituted with a substituent selected from the group comprising: halogen, cyano, nitro, hydroxy, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 haloalkyl, C1-6 haloalkoxy, NR6R7, C3-6 cycloalkylamino, C1-6 alkylthio, Cι-6 alkylthio(C1-6 alkyl), C1-6 alkylcarbonylamino, C(O)NR8R9, sulphonamido (S(O)2NH2), (di)C1-6 alkylsulphonamido and C(O)R10-substituted C1-6 alkyl or C1-6 alkoxy groups; R10 is hydroxy or NRUR12 group; and, R6, R7 R8, R9, Ru, R12, R13 and R14 are independently hydrogen or C1-6 alkyl.
9. A compound of formula (I) as claimed in any one of the preceding claims wherein the 3- to 10-membered saturated or unsaturated ring system in the group R5 is cyclobutyl, cyclopentyl, cyclohexyl, norbornylenyl, adamantyl, phenyl, naphthyl, furyl, thienyl, pynolyl, 2,5-dihydro-lH-pynolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, a pyridinyl, a pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl, benz[b]thienyl, 2,3-dihydrobenz[b]thienyl, indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl, 2,3-dihydrobenzthiazolyl, 1,2,3- benzothiadiazolyl, an imidazopyridinyl, thieno[3,2-b]pyridin-6-yl, benzo[l,2,3]tbiadiazolyl, 2,1,3-benzothiadiazolyl, benzofurazan, quinoxalinyl, a dihydro-1-benzopyryliumyl, 3,4-dihydro-lH-2,l-benzothiazinyl, a pyrazolopyridine, apurine, a pyrazolopyrimidinyl, a thienopyrimidinyl, a tMazolopyrirnidinyl, quinolinyl, isoquinolinyl (for example in 2H-isoquinolin-l- one-yl), quinoxalinyl, a naphthyridinyl, chromonyl, 1,3-benzodioxolyl, a benzothiazinyl, benzo[d]imidazo[2,l-b]thiazol-2-yl or dibenzothiophenyl; or an N- oxide thereof, or an S-oxide or S-dioxide thereof.
10. A process for preparing a compound of formula (I) as claimed in claim 1 comprising reacting a compound of formula (III):
Figure imgf000067_0001
with a compound of formula (IN):
O
■R" (IV) wherein L is a leaving group.
11. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.
13. The use of a compound of the formula (I) as claimed in claim 1, or a phaπnaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy.
14. The use of a compound of a formula (I) as claimed in claim 1 , or a phaπnaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis in a warm blooded animal.
15. A method of treating a CCR3 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound of formula (I) as claimed in claim 1.
PCT/SE2001/001869 2000-09-04 2001-08-30 Chemical compounds WO2002020484A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01963655A EP1322611A1 (en) 2000-09-04 2001-08-30 Chemical compounds
JP2002525106A JP2004508355A (en) 2000-09-04 2001-08-30 Chemical compound
AU2001284584A AU2001284584A1 (en) 2000-09-04 2001-08-30 Chemical compounds
US10/344,758 US7304077B2 (en) 2000-09-04 2001-08-30 Chemical compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0021670.5 2000-09-04
GBGB0021670.5A GB0021670D0 (en) 2000-09-04 2000-09-04 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2002020484A1 true WO2002020484A1 (en) 2002-03-14

Family

ID=9898798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001869 WO2002020484A1 (en) 2000-09-04 2001-08-30 Chemical compounds

Country Status (6)

Country Link
US (1) US7304077B2 (en)
EP (1) EP1322611A1 (en)
JP (1) JP2004508355A (en)
AU (1) AU2001284584A1 (en)
GB (1) GB0021670D0 (en)
WO (1) WO2002020484A1 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004487A1 (en) * 2001-07-02 2003-01-16 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2003018556A1 (en) * 2001-07-23 2003-03-06 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2003072554A1 (en) * 2002-02-28 2003-09-04 Takeda Chemical Industries, Ltd. Azole compounds
US6887871B2 (en) 2000-02-23 2005-05-03 Astrazeneca Ab Use of phenylheteroakylamine derivatives
US6900243B2 (en) 2000-02-23 2005-05-31 Astrazeneca Ab Phenylheteroalkylamine derivatives
WO2005073192A1 (en) * 2004-02-02 2005-08-11 Astrazeneca Ab Novel piperidines as chemokine modulators (ccr)
US6953797B2 (en) 2000-02-23 2005-10-11 Astrazeneca Ab Use of phenylheteroalkylamine derivatives
WO2006064189A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
WO2007015666A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt i
WO2007015667A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt ii
WO2007015668A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt iii
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7223794B2 (en) 2001-07-31 2007-05-29 Astrazeneca Ab Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US7348341B2 (en) * 2000-05-31 2008-03-25 Astrazeneca Ab Chemical compounds
WO2008025857A3 (en) * 2006-09-01 2008-06-19 Apoxis Sa New method for the treatment of inflammatory diseases
WO2008144268A1 (en) * 2007-05-15 2008-11-27 Boehringer Ingelheim International Gmbh Urotensin ii receptor antagonists
US7473711B2 (en) 2004-04-22 2009-01-06 Pfizer Inc. Androgen modulators
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7528156B2 (en) 2000-06-20 2009-05-05 Astrazeneca Ab Compounds
US7576128B2 (en) 2004-02-13 2009-08-18 Pfizer Inc. Androgen receptor modulators
US7674819B2 (en) 2005-05-05 2010-03-09 Warner-Lambert Company Llc Androgen modulators
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
US7994179B2 (en) 2007-12-20 2011-08-09 Astrazeneca Ab Carbamoyl compounds as DGAT1 inhibitors 190
US8003676B2 (en) 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
US8017781B2 (en) 2005-11-15 2011-09-13 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US8168827B2 (en) 2003-05-20 2012-05-01 Ajinomoto Co., Inc. Amide derivative
US8188092B2 (en) 2009-06-19 2012-05-29 Astrazeneca Ab Substituted pyrazines as DGAT-1 inhibitors
US8304438B2 (en) 2006-12-20 2012-11-06 Sanofi Heteroarylacrylamides and their use as pharmaceuticals
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
US9309238B2 (en) 2009-11-05 2016-04-12 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US10919888B2 (en) 2015-09-17 2021-02-16 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
EP4159725A4 (en) * 2020-05-29 2023-12-20 Daegu-Gyeongbuk Medical Innovation Foundation Carboxamide derivative and pharmaceutical composition comprising same as active ingredient for preventing or treating mental illness

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102809D0 (en) * 2001-08-22 2001-08-22 Astrazeneca Ab Novel compounds
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
KR20090016629A (en) * 2006-06-08 2009-02-16 아스트라제네카 아베 Benzimidazoles and their use for the treatemnt of diabetes
RU2010102990A (en) * 2007-08-17 2011-09-27 Астразенека Аб (Se) Oxadiazole derivatives as DGAT inhibitors
TW201024271A (en) * 2008-12-19 2010-07-01 Astrazeneca Ab Chemical compounds 553

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515240A1 (en) * 1991-05-03 1992-11-25 Sanofi N-alkylidene piperidine compounds and their enatiomers, process for their preparation and pharmaceutical compositions containing them
WO1997010207A1 (en) * 1995-09-12 1997-03-20 Kyorin Pharmaceutical Co., Ltd. Novel benzamide derivatives
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1243991A (en) 1968-06-10 1971-08-25 Ici Ltd Piperidine, morpholine and piperazine derivatives
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
DK159420C (en) 1983-03-09 1991-03-11 Ciba Geigy Ag N- (PIPERIDINYL-ALKYL) CARBOXAMIDES AND SALTS THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THE USE OF THE COMPOUNDS FOR THE PREPARATION OF ANTI-CYPOTIC PHARMACEUTICAL PREPARATIONS
FI853478L (en) * 1984-09-14 1986-03-15 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV FENYLALKYLFOERENINGAR.
CA1246074A (en) 1984-12-05 1988-12-06 Albertus H.M.T. Van Heertum Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
KR910006138B1 (en) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 Cyclic amine derivatives
EP0429341A3 (en) 1989-11-20 1991-11-13 Rhone-Poulenc Sante Heterocyclic derivatives, their preparation and pharmaceuticals containing them
JP2860689B2 (en) 1990-03-14 1999-02-24 第一製薬株式会社 Pyrimidine derivatives
FR2667317B1 (en) * 1990-10-02 1992-12-04 Synthelabo 2-AMINOPYRIMIDINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
FR2675801A1 (en) 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, their preparation and the medicaments containing them
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
EP0661266A1 (en) 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
FR2724382B1 (en) 1994-09-13 1996-10-18 Synthelabo 2-AMINOPYRIMIDINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ES2087038B1 (en) 1994-11-07 1997-03-16 Uriach & Cia Sa J NEW PIPERIDINES WITH ANTAGONIST ACTIVITY OF THE PAF.
KR19980703192A (en) 1995-03-22 1998-10-15 우에하라아끼라 Thiazole derivatives
JP2000506904A (en) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション Dihydropyrimidines and uses thereof
EP0912505A4 (en) 1996-06-27 2001-10-24 Smithkline Beecham Corp Il-8 receptor antagonists
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2927248B2 (en) 1996-08-08 1999-07-28 株式会社日立製作所 Constant velocity joint
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2002501898A (en) 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド Cyclic amine modulators of chemokine receptor activity
PT1131291E (en) 1998-11-17 2005-01-31 Hoffmann La Roche ANTAGONISTS III OF THE 4-AROIL-PIPERIDIN-CCR-3 RECEPTOR
EP1140834A1 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002022572A2 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
WO2002030899A1 (en) 2000-10-09 2002-04-18 Novartis Ag N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
SE0102809D0 (en) * 2001-08-22 2001-08-22 Astrazeneca Ab Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515240A1 (en) * 1991-05-03 1992-11-25 Sanofi N-alkylidene piperidine compounds and their enatiomers, process for their preparation and pharmaceutical compositions containing them
WO1997010207A1 (en) * 1995-09-12 1997-03-20 Kyorin Pharmaceutical Co., Ltd. Novel benzamide derivatives
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887871B2 (en) 2000-02-23 2005-05-03 Astrazeneca Ab Use of phenylheteroakylamine derivatives
US6900243B2 (en) 2000-02-23 2005-05-31 Astrazeneca Ab Phenylheteroalkylamine derivatives
US6953797B2 (en) 2000-02-23 2005-10-11 Astrazeneca Ab Use of phenylheteroalkylamine derivatives
US7348341B2 (en) * 2000-05-31 2008-03-25 Astrazeneca Ab Chemical compounds
US7528156B2 (en) 2000-06-20 2009-05-05 Astrazeneca Ab Compounds
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2003004487A1 (en) * 2001-07-02 2003-01-16 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2003018556A1 (en) * 2001-07-23 2003-03-06 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7265227B2 (en) 2001-07-23 2007-09-04 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7223794B2 (en) 2001-07-31 2007-05-29 Astrazeneca Ab Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
WO2003072554A1 (en) * 2002-02-28 2003-09-04 Takeda Chemical Industries, Ltd. Azole compounds
US7183276B2 (en) 2002-02-28 2007-02-27 Takeda Pharmaceutical Company Limited Azole compounds
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
US8168827B2 (en) 2003-05-20 2012-05-01 Ajinomoto Co., Inc. Amide derivative
WO2005073192A1 (en) * 2004-02-02 2005-08-11 Astrazeneca Ab Novel piperidines as chemokine modulators (ccr)
US7956070B2 (en) 2004-02-02 2011-06-07 Astrazeneca Ab Piperidines as chemokine modulators (CCR)
US7576128B2 (en) 2004-02-13 2009-08-18 Pfizer Inc. Androgen receptor modulators
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
US7473711B2 (en) 2004-04-22 2009-01-06 Pfizer Inc. Androgen modulators
AU2005315430B2 (en) * 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
WO2006064189A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
US7674819B2 (en) 2005-05-05 2010-03-09 Warner-Lambert Company Llc Androgen modulators
US7799823B2 (en) 2005-05-05 2010-09-21 Warner-Lambert Company Llc Androgen modulators
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
US8148405B2 (en) 2005-08-02 2012-04-03 Astrazeneca Ab Salt I
WO2007015667A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt ii
WO2007015666A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt i
WO2007015668A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt iii
US8445681B2 (en) 2005-11-15 2013-05-21 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US8017781B2 (en) 2005-11-15 2011-09-13 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
US8017603B2 (en) 2005-12-22 2011-09-13 Astrazeneca Ab Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors
US8003676B2 (en) 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
WO2008025857A3 (en) * 2006-09-01 2008-06-19 Apoxis Sa New method for the treatment of inflammatory diseases
US8304438B2 (en) 2006-12-20 2012-11-06 Sanofi Heteroarylacrylamides and their use as pharmaceuticals
WO2008144268A1 (en) * 2007-05-15 2008-11-27 Boehringer Ingelheim International Gmbh Urotensin ii receptor antagonists
US8258301B2 (en) 2007-05-15 2012-09-04 Boehringer Ingelheim International Gmbh Urotensin II receptor antagonists
US7994179B2 (en) 2007-12-20 2011-08-09 Astrazeneca Ab Carbamoyl compounds as DGAT1 inhibitors 190
US8188092B2 (en) 2009-06-19 2012-05-29 Astrazeneca Ab Substituted pyrazines as DGAT-1 inhibitors
US9309238B2 (en) 2009-11-05 2016-04-12 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
US9908876B2 (en) 2009-11-05 2018-03-06 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
US10913737B2 (en) 2009-11-05 2021-02-09 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
US11820767B2 (en) 2015-09-17 2023-11-21 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
US10919888B2 (en) 2015-09-17 2021-02-16 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US10988457B2 (en) 2019-01-30 2021-04-27 Insilico Medicine Ip Limited TLR inhibitors
EP4159725A4 (en) * 2020-05-29 2023-12-20 Daegu-Gyeongbuk Medical Innovation Foundation Carboxamide derivative and pharmaceutical composition comprising same as active ingredient for preventing or treating mental illness

Also Published As

Publication number Publication date
US20040102432A1 (en) 2004-05-27
JP2004508355A (en) 2004-03-18
AU2001284584A1 (en) 2002-03-22
GB0021670D0 (en) 2000-10-18
US7304077B2 (en) 2007-12-04
EP1322611A1 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
US7304077B2 (en) Chemical compounds
EP1546130B1 (en) Piperidine derivatives for use in the treatment of chemokine mediated disease states
US7265227B2 (en) Piperidine derivatives useful as modulators of chemokine receptor activity
US6960602B2 (en) Piperidine derivatives as modulators of chemokine receptors
US7709500B2 (en) Chemical compounds
US20030166652A1 (en) Chemical compounds
EP1404667B1 (en) Piperidine derivatives useful as modulators of chemokine receptor activity
US20090069325A1 (en) Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity
US7238691B2 (en) Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
EP1363902B1 (en) Chemical compounds
US20040266823A1 (en) Novel piperidine derivatives as modulators of chemokine receptors
US7482363B2 (en) Piperidine derivatives useful as modulators of chemokine receptor activity
WO2002079156A1 (en) Novel piperidine derivatives as modulators of chemokine receptor
NZ541682A (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001963655

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10344758

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002525106

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001963655

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642